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ABSTRACT
RARE DISEASES IN THE UNITED STATES: ESTABLISHING
PREAVELENCE, THE INSURANCE EXPERINECE, AND ORPHAN
DRUG EXPENDITURES IN MEDICARE PART D
MAY 2020
TAI SPARGO PASQUINI, B.A., AMERICAN UNIVERSITY
M.P.A., AMERICAN UNIVERSITY
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Michael E. Begay
In the United States, there are an estimated 30 million people living with one or
more rare diseases. Each rare disease impacts fewer than 200,000 people. Small patient
populations create research and medical challenges. Patients and the healthcare system
experience high costs. To adequately address patient needs and prepare our healthcare
system, it is critical that we conduct research that contextualizes the U.S. rare disease
experience.
This dissertation includes three related studies that look at the U.S. rare disease
experience. The first paper investigates the availability and data quality of rare disease
prevalence estimates and the healthcare infrastructure that could be utilized to establish
future estimates. The paper found that prevalence estimates rarely follow best practices in
data quality. U.S. healthcare infrastructure is ill-equipped to track rare diseases and
produce future prevalence estimates. This could impact our ability to realize and
equitably administer healthcare innovations, including precision medicine.
vi

The second paper looked at the caregiver experience navigating health insurance
using a grounded theory qualitative approach. The paper found that rare disease
caregivers feel it is imperative to learn how to navigate insurance, especially since health
setbacks are costly and disruptive. Insurance companies are rarely knowledgeable about
the disease and interactions are time intensive. Parents are required to meticulously track
benefits to balance long-term medical needs and financial stability.
The third paper investigated orphan drug expenditures in Medicare Part D from
2013 to 2017. The study found that orphan only drugs represent 8.67% and partial orphan
drugs represent 6.74% of total aggregate costs. In 2017, the average cost per beneficiary
for orphan drugs was $92,753 and $3,920 for common drugs. Almost half of orphan drug
costs are attributed to beneficiaries under age 65.
Together, these studies point to the need to invest in our healthcare system and
explore programs that can address issues of access for patients. Currently, our system is
not equipped to address patient needs and current funding increases are not sustainable.
Policy considerations, such as a rare disease national plan, could help ensure rare disease
patient needs are addressed in a methodical way.
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CHAPTER 1
INTRODUCTION
In the United States, there are an estimated 30 million people living with one or
more rare diseases.1 Rare diseases are defined in the U.S. as a condition impacting fewer
than 200,000 people.2,3 There are an estimated 6,500-7,000 rare diseases.3 The small
patient population for each disease creates challenges for research; including for basic
epidemiological data, natural history studies, and clinical trials for the development of
treatments.4–9 The lack of research and awareness also means that many medical
professionals and health insurance companies are unfamiliar with the disease and patients
may struggle to find basic information about their condition.4,10 This can lead patients and
their caregivers to feel isolated or unsupported in their attempts to find information or
resources.6 Additionally, many patients face financial challenges when seeking care.11–15
“Financial toxicity” is a term identified in the cancer literature to describe the impact of
economic stress that can impact a patient’s overall well-being, however, this phenomenon
is not unique to the cancer community.11–14
An orphan drug is a treatment that has an indication for a disease with an
estimated population of less than 200,000 people in the U.S. or where it is unlikely the
manufacturer will be able to recoup the costs of manufacturing the drug.2 Orphan drug
designation occur as part of the Food and Drug Administration’s (FDA) drug approval
process.16 Roughly 300 rare diseases (less than 5%) have an FDA approved orphan
drug.17 The Orphan Drug Act of 1983 established economic incentives to encourage the
research and development of orphan drugs, including 7-year market exclusivity and feewaivers.2 In 2017, the invoice prices of orphan drugs indicated that the median annual
1

cost was over $46,800 per year and the mean was $87,319.18 The average sales for the 50
highest cost orphan drugs was $639.5 million in 2017.18 The high cost of orphan drugs in
the U.S. has resulted in criticisms related to the incentive structures and other
pharmaceutical company efforts to maximize their profits.19–24
Challenges faced by rare disease patients are largely universal and are often
approached as an international public health challenge. Although rare diseases are
clinically heterogenous, challenges such as diagnosis, finding knowledgeable medical
providers, and accessing treatments and services are often similar across different disease
states.4,6 Approaching rare diseases on a global scale allows for international
collaboration and knowledge sharing that is critical when resources are limited. There
have been concerted international efforts to bring consistency to the nomenclature of rare
diseases,25–27 increase the visibility of rare diseases in healthcare infrastructure,28,29
establish estimated prevalence,30 and establish national priorities for rare diseases.31
However, there are gaps in the regarding how international efforts are being
implemented, how patients are being impacted, and what infrastructure exists to support
these efforts in the United States.
Although there is a considerable body of research on healthcare access for other
patient populations, few studies focus on rare disease patients as a group or the U.S.
capacity to provide access to care. This dissertation research is comprised of three papers
that look at different topics related to rare diseases and components of the U.S. healthcare
system. The first paper explores the data quality of available prevalence estimates and the
infrastructure that exists to establish future prevalence estimates for a sample of rare
diseases. Prevalence is a fundamental component of understanding a disease,
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appropriately planning for health expenditures, and educating key stakeholders about the
disease. The second paper is a qualitative study with caregivers whose children are living
with metachromatic leukodystrophy (MLD) or spinal muscular atrophy (SMA) that used
a grounded theory approach to describe caregivers’ perceptions of the health insurance
experience. The third paper investigates the expenditures of orphan drugs in Medicare
Part D from 2013 to 2017.
Together, this research provides an assessment of U.S. specific infrastructure,
insurance access, and public program spending trends for rare diseases and orphan drugs.
Individuals living with rare diseases are estimated to represent 10% of the U.S.
population, but much of our understanding about the rare disease experience comes from
international studies or studies that focus on an individual rare disease. This research will
contribute to our knowledge of the patient experience and how policymakers should
invest in our healthcare system infrastructure to better prepare for current and future
health needs.
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CHAPTER 2
RARE DISEASE PREVALENCE QUALITY AND
INFRASTRUCTURE IN THE UNITED STATES
Background
Rare diseases
In the United States, the Orphan Drug Act (ODA) and the National Institutes of
Health (NIH) define rare diseases as conditions with less than 200,000 active cases.1,2 In
the European Union, a disease affecting fewer than 5 in 10,000 people is considered
rare.3 The Genetic and Rare Diseases Information Center (GARD) at NIH currently lists
over 6,500 rare diseases.1 Rare diseases impact a variety of body systems and the clinical
manifestations of rare diseases are heterogenous. Disease onset can occur at any age and
conditions can be either acute or chronic, but many are debilitating. Although little is
known about the causes of most rare diseases, an estimated 80% are thought to have a
genetic component.4 Exposure to environmental toxins, infections, adverse reactions to
therapies, or immune responses are other known factors of onset, but for some conditions
the cause is never identified.1,4 Due to the limited research, knowledge, and treatment
options, many rare conditions are fatal.4,5 It is often difficult for patients to receive an
accurate diagnosis or to find other individuals with the condition.5–7 Research for rare
diseases can be difficult based on the small and dispersed patient population.
Rare cancers share the same definition and many of the same challenges.8 One
study found that 60 of 71 forms of cancer are considered rare in adults.9 Additionally, in
another study of cancerous tumors between 22-25% have been estimated to be rare.11
Rare cancers have been reported to have a five-year survival rate of 47% compared to a
7

five-year survival rate of 65% for common cancers.8 Rare cancers are often divided into
more specific subtypes based on genetic characteristics, meaning that even common
cancers are becoming increasingly rare.8 Despite limited research overall, rare cancers
may benefit from efforts to research common cancers.8,10
Importance of estimating the prevalence of rare diseases
Estimating the burden of disease is a critical public health function. For most rare
diseases, basic information such as the natural history of the disease and epidemiological
data is limited or missing.5,6 Very little is known about the exact prevalence of most rare
diseases, both in the U.S. and globally.5 A commonly referred to figure estimates
between 25 to 30 million Americans are living with one or more rare diseases,11 but this
is a difficult claim to substantiate as the original source and methodology of this
estimation is difficult to identify.
Knowing prevalence of a disease provides a baseline to track inequities in the
impacted population or identify changes in disease burden that may be based on
environmental exposures, social determinants of health, or structural barriers to care. In
rare cancers, there is evidence that the distribution, incidence rates, and types can vary by
region,12 but, without epidemiological data, the cause for these differences cannot be
explored. Researchers at the World Health Organization also hypothesized that
epidemiological data contributed to the increased number of treatments and resulting
health benefits for rare cancers and inborn errors of metabolism.5 Understanding trends in
morbidities and mortality is necessary to inform a logical approach for disease response
and planning.
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Healthcare allocation decisions rely on strong epidemiological and actuarial data
related to the expected healthcare needs and expenditures of the population an entity or
provider serves. Understanding needs across a population can help identify the specialists
that will be needed by patients and gaps in services. Estimating the financial impact is
also important to plan for individual out-of-pocket expenditures and the costs associated
with disease management. These costs are often high and a source of stress for patients
and families.13,14 “Financial toxicity” is a growing concept in the research literature that
describes the personal and treatment related financial burden faced by patients,
particularly patients with cancer.15,16
Identifying patients with rare diseases can help inform policies to address the
financial burden to individuals and the healthcare system. Patient identification is
important for ensuring a patient base for future clinical trial research.17 It is critical to
develop evidence-based research on the natural history of a disease and the anticipated
disease progression. Knowing the number of people impacted by a disease can help
inform decisions about clinical trial designs and the best way to gather scientific evidence
for developing treatment protocols. Treatments may only be effective in a portion of
patients, understanding the total number of people impacted by a condition allows a more
thoughtful evaluation of clinical effectiveness.
Prevalence in orphan drug research and development
The Orphan Drug Act (ODA) incentivizes research and development of rare
disease products through fee waivers and seven-year marketing exclusivity.2 These
benefits are based on the estimated prevalence of the targeted disease. Companies
developing a product submit an application to the Food and Drug Administration (FDA)

9

to establish eligibility for obtaining an orphan designation.18 Drugs are eligible for an
orphan designation if they are intended to treat a disease that affects fewer than 200,000
people in the U.S. and there is no expectation of recovering the research, development,
and marketing costs from U.S. sales of the drug. This process can occur at any point in
the drug development process, anytime between laboratory drug discovery and clinical
trials.18 Once the safety and efficacy of the drug has been established through clinical
trials, the FDA determines the final indications for the drug’s marketing approval.18
Between January 1983 and August 2018, 503 drugs were approved with an orphan
indication for drug approval.
Despite the small market for orphan drugs, the pharmaceutical industry has
demonstrated the potential for large profits.19,20 Of the estimated 6,500 rare diseases only
about 300 diseases currently have a FDA approved treatment, leaving many patients
desperate for successful treatments.21 Some of the criticisms of the ODA include the
allegation that incentives are exploited to develop drugs that may fall outside of the
intended scope of the law.19 Of all orphan designation applications received between
2008 and 2017, 71% were for drugs intended to treat diseases impacting fewer than
100,000 people18 and the average estimated patient population per orphan therapy was
5,730.22 Rare cancers have been estimated to represent roughly 30% of orphan drug
approvals and up to 43% of orphan indications, which is a higher percentage than drugs
to treat any other category of orphan drug therapeutic use.5,18,22,23
As part of the orphan drug application process the FDA requires prevalence data
with references to the estimates’ sources; outdated or international sources need to be
justified and contextualized for the relevance to the U.S.18,24 The pharmaceutical
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companies provide these estimates and the FDA validates them. However, in a 2018
Government Accountability Office (GAO) report, the independent verification of
population estimates were not conducted for 23 of 148 review templates and for 15 of the
applications for drugs that were ultimately approved.18 Skipping this verification was
cited by GAO as one of the concerns related to the review process, but does not
acknowledge the difficulty in finding and verifying these numbers.
Measures for establishing disease prevalence
There are many ways to describe the number of people living with a particular
disease and different stakeholders have varying priorities that may lead to the use of
different metrics. Prevalence refers to the number or proportion of people who have a
particular condition in a population at a particular time.25 This can refer to a point
prevalence, the number of cases at a specified point in time; or period prevalence, the
number of cases over a specified period of time.25 These estimates may account for
changes based on mortality and newly identified cases. Incidence describes the
proportion of new cases in a time interval.25 Incidence can be expressed as a cumulative
rate, the total number of new cases, the number of new cases per unit of a population, or
as a measurement of risk. This paper will refer to prevalence, as this is the measurement
used for rare diseases in the U.S. and was identified as the preferred epidemiological
metric in rare disease definitions internationally.26 For some rare diseases the total
number of identified patients is so small that the estimated disease prevalence is
described as the number of estimated cases.27
Many study factors can impact these estimates including the sample population,
the time frame of interest, the data collection methods, the study design, the tools utilized,
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and the methodologies used for data analysis.25 Prevalence data can come from a variety
of sources including the medical literature, “umbrella” organizations that represent a
group of related rare diseases, disease specific organizations, government, industry,
medical records, medical institutions, insurance claims data, and health foundations.28
When attempting to estimate the number of individuals impacted by a rare
condition, it is first necessary to determine if a sample would be adequate, or if the
disease population is so small that a sample is unable to accurately establish population
level prevalence.29 For example, in one study that reviewed laboratory samples from
1,825 patients who had two indicator symptoms for lysosomal acid lipase deficiency,
none of the patients in the study were found to have the disease.30 Rare diseases estimates
may require infrastructure that has been established to collect prevalence data for the
disease of interest as other methods may not capture cases of the disease.
Registries
A registry is a tool to collect and store data. Commonly identified goals include to
identify a list of patients, to perform natural history studies, and to support research
objectives such as for product and treatment evaluation.31–33 Rare disease registries have
been developed by patient organizations, government entities, and industry. Medical
centers or designated disease programs within hospitals or treatment centers are also
natural settings to establish disease registries.34
Disease registries are well established as a data source for providing population
estimates for diseases.31,32,35,36 High-quality data relies on well-defined diagnostic
criteria.29,37 This can be complicated when multiple sites or investigators are involved or
if there are subsets of the disease of interest.29 Registries often require participants to opt-
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in. Some diseases may be covered under multiple registries, which increases duplication
and can divide resources. Privacy laws limit the opportunity to cross-check redundancy
across different systems.37,38 It is also important to make the distinction between
duplicate records and individuals who may appear multiple times because they have
multiple qualifying conditions to be added to the registry.39
If a registry is not compulsory for all patients, there may be a selection bias in the
type of patients who decides to participate or who are referred to the registry.29 Patients
who have more mild forms of a disease or whose care can be managed by their own
physician are less likely to be referred to specialty centers or seek out additional care.
Patients may be limited in their ability to travel to specialty medical centers and it is not
feasible to have multiple geographically diverse centers for diseases with a small
population.40 Age of diagnosis could also impact where a patient seeks care.41
Participation may also be influenced by a patient’s perception of his or her benefit, such
as the availability of therapies or cultural feelings of trust in the medical system.29
There are a few registries in the U.S. that may provide an opportunity to estimate
prevalence for the included rare diseases. The Rare Disease Clinical Research Network
(RDCRN), a network of rare disease centers of excellence within NIH, oversees a
voluntary patient contact registry.42 The Surveillance, Epidemiology, and End Results
Program (SEER) at the National Cancer Institute at NIH tracks cancer rates through
registries in a sample of states which provides coverage for 34.6% of the population.43
The Centers for Disease Control and Prevention (CDC) funds a program to collect
information about rare bleeding disorders and patient demographic information through a
network of nationwide Hemophilia Treatment Centers.44,45
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Data within a registry often requires further investigation before prevalence can
be reported. One study was conducted to assess the quality of data and provide
prevalence estimates for diseases in RARECARE, a European based rare cancer
registry.46 The study found differences in the level of uniformity and accuracy of the
classification across the different types of rare cancers.46 Without clear diagnostic
criteria, it is often difficult to consistently code and track cases of diseases. Statistical
analysis to validate estimates often requires comparisons from other data sources, which
may or may not be available for rare diseases, which makes it challenging to validate
disease estimates.37,39
Surveillance and required reporting
Surveillance is the ongoing collection, analysis, and interpretation of data to help
prevent disease and injury and to provide scientific evidence for program and policy
decisions.47,48 This can include passive surveillance of all clinical interactions at certain
institutions, syndromic surveillance based on clinical features, and sentinel surveillance
where certain institutions or groups agree to report all cases of a defined condition, often
these are for disease outbreaks or bioterrorism.47 There are tradeoffs between the
sensitivity of detecting an event and the simplicity, timeliness, and cost of inclusion.48
The ability to control or prevent the disease is often seen as the most compelling reason
to invest in a surveillance system, but other justifications include tracking medical costs
or mortality rates associated with the condition.47,48 The costs of establishment,
infrastructure, and maintenance of surveillance systems can be high, but the benefits
include the potential for long-term cost savings especially if successful interventions are
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established. Data collected through surveillance are less likely than other methods of
disease identification to disproportionally include more severe forms of the condition.49
There are international examples of required rare disease reporting. For example,
Italy established a country-wide network of accredited centers to serve rare disease
patients and mandated that new cases be reported to the National Registry of Rare
Diseases, which now provides country specific incidence measures for rare diseases
based on population level data.50 Rare diseases are not systematically required to be
reported in the U.S., but some conditions may be captured in other official public health
surveillance systems. For example, the National Notifiable Disease Surveillance System
(NNDSS) at the CDC collects information on a set of infectious diseases across the entire
U.S.51 Concerns about morbidity and mortality in children, has led to targeted pediatric
surveillance efforts for some rare diseases.52 Currently, 43 states have birth defects
tracking programs, 14 of which are funded by the CDC.53 The Recommended Uniform
Screening Panel is a list of disorders that have been identified by the Secretary of the
Department of Health and Human Services for inclusion in state newborn screening
programs.54 However, states decide what is included on newborn screening panels, which
creates differences across jurisdictions.49
Disease terminologies and coding systems
Genetic and rare diseases are generally underrepresented in coding systems.55
Both registries and surveillance systems are dependent on clear and consistent disease
identification and coding to maximize the potential for discovery and clinical use.56
These systems are used by a variety of audiences and were established for different
purposes including electronic health records and insurance claims. There have been
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efforts to increase rare disease visibility in health information systems and to increase
interoperability between databases.57–60 Classification systems need to account for
descriptive and genetic information, especially as new conditions are observed. One of
the challenges is mapping the terminologies across the existing resources and coding
platforms that are used to identify and describe rare diseases. A study that looked at
consistency in coding case reports for a sample of rare diseases found that professional
coding companies were in agreement on the core concepts 33% of the time.61
International Classification of Diseases (ICD) codes are used to code diagnoses,
symptoms, and procedures.62 Globally they are used to track disease statistics and trends.
In the U.S. they are primarily used for billing purposes. The U.S. first adopted the ICD-9
codes for use in 1977 and adopted the updated ICD-10 codes on January 1, 1999.63,64 ICD
codes are used in studies that rely on hospital discharge data, insurance claims, and
mortality records.65 Most rare diseases are absent from the ICD-10 codes and diseases
that do exist are often misclassified.66
One study found that of the 6,519 rare diseases listed by NIH, 11% were broadly
included in ICD-9 and 21% in ICD-10.57 The study also found that only 25% of the ICD10 codes were for only one disease, limiting the level of specificity that can be garnered
from the data. There are many examples of rare diseases that do not have any ICD code.
If a disease does not have a specific ICD code, researchers must investigate medical
records or use proxy indicator variables to create algorithms to identify the disease of
interest from claims data. This requires dedicated resources to validate information for
each condition of interest.
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Studies to assess the accuracy of ICD code or administrative data in identifying
cases of rare diseases have had mixed results.65,67–73 The clarity of the case definition and
the number of clinical visits by the patient increased the accuracy identifying disease
cases. Studies that used only ICD codes to assess true cases of rare diseases found
between 15% and 65% accuracy in identifying cases.65,68,69,74 Differences in the accuracy
and completeness of capturing cases of a disease between data sets highlights the
necessity of cross-validating cases. For example, in a validation study to see if muscular
dystrophy cases were accurately identified in claims and hospital discharge data, 74.02%
of cases in the claims data were not included in the hospital discharge records.65
Reference data sets or records to validate cases are not always available for rare diseases.
The European Commission called for an investment in increasing rare disease
representation, which will be reflected in the ICD-11 revisions that are being developed
by the World Health Organization; currently over 5,000 rare diseases are listed in this
new system.62,66 The roll out and implementation of ICD-11 in the U.S. is unknown. The
complexities of accurate coding, especially for diseases that clinicians are unfamiliar
with, will continue to be a barrier for finding and identifying disease cases.
Challenges in estimations for rare diseases
Accurate estimates are often impacted by diagnosis related challenges, with many
rare disease organizations and patients claiming that the actual prevalence is greater than
the currently identified population.6 The small patient population also makes it more
difficult to establish tracking systems as the population is likely geographically disbursed
and difficult to identify. This increases the need for collaboration, but there is evidence
that some centers are hesitant to join multi-site trials due to fears of low patient accrual,
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increased regulatory burden, or unclear benefits.17 Rare diseases are competing for
limited funding, which can mean an investment in the infrastructure to establish biobanks
and registries may be hard to justify.12,38
In Europe there has been an investment in establishing prevalence and
encouraging country specific rare disease plans.27,75 A preliminary report was released to
provide initial data on rare disease prevalence for a sample of conditions.76 Some
therapeutic categories such as pediatric oncology and rare blood disorders are also
creating frameworks to address healthcare challenges.38,41 In the U.S., leaders at NIH and
FDA have outlined priorities to address core rare disease challenges faced by patients
with rare diseases.28 This includes increasing current knowledge of rare diseases,
additional partnerships with patient organizations, and the need to track genetic
variability and environmental factors for use in future research.28,77
Policymakers, patients, medical professionals, researchers, and industry all have
an interest in understanding the impact of a disease. Understanding prevalence impacts
healthcare allocation decisions and industry incentives. The GAO has indicated the need
for increased investment in verification of prevalence data in FDA drug application
reviews. Researchers rely on epidemiological data to make decisions related to the
robustness of data for natural history and treatment protocols. Previous rare disease
prevalence studies have evaluated a single disease78,79 or coding systems62,80 without
considering other types of infrastructure. It is important to evaluate rare diseases at a
systems level and determine if disease characteristics impact the availability of
prevalence estimates or the available infrastructure. To date, there have been no studies to
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quantify the scope of our knowledge for U.S. based prevalence estimates or the potential
to leverage current infrastructure to provide prevalence estimates in the future.
Methods
Objectives
This study seeks to explore two inter-related questions; what is the quality of the
existing prevalence estimates for a sample of rare diseases in the United States and what
infrastructure is in place that may be used to ascertain prevalence estimates in the future.
The research questions for this study are:
1. What is the availability and data quality for prevalence estimates for a sample of
rare diseases in the United States?
2. What infrastructure is available that has the potential to facilitate generating valid
prevalence estimates for a sample of rare diseases in the United States?
3. Is there a difference in the availability, information quality, or infrastructure for
estimates of rare disease prevalence in the United States for diseases that:
a. have an orphan drug approval compared to those that do not have an
orphan drug approval?
b. are rare cancer compared to diseases that are not cancer?
Conceptual model
Cleveland’s model of the healthcare environment is the conceptual framework
utilized for this study.81 (Figure 1) The model underscores the importance of information
and technology for three key arenas in healthcare; clinical practice, healthcare consumers,
and research. The model was originally developed to inform the needs of health
information education, but provides a framework for understanding the interplay between
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information and technology advancement in the broader healthcare environment.
Technological advancement and additional healthcare information simultaneously drive
innovation and must be responsive to healthcare practice and research needs. The model
is impacted by both internal and external factors including the structure of the healthcare
system and the values and goals of healthcare delivery.81
Figure 1: Cleveland's model of the healthcare environment

This study is driven by the informational importance of rare disease prevalence
data. This information is critical for establishing information about patients (consumers)
and for creating clinical practice guidelines. Clinical practice is informed by natural
history of disease progression, which is predicated on understanding the population
impacted by a disease. Epidemiological, healthcare utilization, and product development
research all require an understanding of the total population impacted. Technological
solutions such as registries provide data for determining prevalence. However, the data
available for prevalence on many health information websites underscore the deficiencies
of our current infrastructure to collect, process, and report reliable information.
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Rare disease sample
To generate a sample of rare diseases, three lists of rare diseases were accessed
from the GARD website; a list of rare cancers, 82 a list of diseases with FDA orphan
drugs,83 and the full list of diseases in the GARD database.84 (Figure 2) Data were
obtained from GARD, the leading U.S.-based government agency for rare disease
information. The rare cancer and orphan drug lists were combined and redistributed into
three groups; rare cancers with an orphan drug (group 1), rare cancers without an orphan
drug (group 2), and non-cancer diseases with an orphan drug (group 3). Group 4, noncancer diseases without an orphan drug, was created by taking the full list and removing
duplicate conditions from any of the other lists. Microsoft Excel was used to categorize
each list and obtain a sample of 20 diseases per group for a purposeful stratified sample
of 80 rare diseases total. (Table 1)
Figure 2: Flowchart for sample diseases by group
The full GARD list includes diseases that are not rare, but are included based on patient
inquiries for information on those conditions. Additionally, disease synonyms are also
included as separate entries on the list which accounts for the large number of duplicate
and not rare conditions.
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Table 1: Diseases included in the sample
Orphan drug

No orphan drug

Group 1

Group 3

Acral lentiginous melanoma

Acute panmyelosis with myelofibrosis

Acute lymphoblastic leukemia

Adrenal medulla cancer

Anaplastic thyroid cancer

Ameloblastic carcinoma

Chronic lymphocytic leukemia

Autoimmune lymphoproliferative

Clear cell renal cell carcinoma

Cancer

syndrome

Ewing sarcoma

Basal cell carcinoma, multiple

Familial prostate cancer

Familial pancreatic cancer

Follicular lymphoma

Familial Wilms tumor 2

Hairy cell leukemia

Gangliocytoma

Kaposi sarcoma

Glassy cell carcinoma of the cervix

Malignant mesothelioma

Goblet cell carcinoid

Melanoma astrocytoma syndrome

Infantile myofibromatosis

Neuroblastoma

Juvenile myelomonocytic leukemia

Oslam syndrome

Multiple endocrine neoplasia type 2B

Papillary thyroid carcinoma

Multiple familial trichoepithelioma

Renal cell carcinoma 4

N syndrome

Soft tissue sarcoma childhood

Nevoid basal cell carcinoma syndrome

Subependymal giant cell astrocytoma

Nijmegen breakage syndrome

Testicular cancer

Oropharyngeal cancer

Thyroid cancer, follicular

Ovarian carcinosarcoma
Von Hippel-Lindau disease

Group 2

Group 4

Cholesteryl ester storage disease

Achard Thiers syndrome

CINCA

Baritosis

Cystinosis

Cercarial Dermatitis

Factor VII deficiency

Chorioretinitis
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Herpes simplex encephalitis

Dubowitz syndrome

Hyperkalemic periodic paralysis

Farber's disease

Keratoconus

Graham-Little-Piccardi-Lassueur

Methylmalonic acidemia with

syndrome

homocystinuria
Not
cancer

Houlston Ironton Temple syndrome

Homocystinuria type cblD

Hutterite cerebroosteonephrodysplasia

Mild phenylketonuria

syndrome

Mucopolysaccharidosis type VI

Hypomandibular faciocranial dysostosis

Myasthenia gravis

Isochromosome Yp
Limb body wall complex

Narcolepsy

Manitoba oculotrichoanal syndrome

Orotic aciduria type 1

Mastocytic enterocolitis

Prader-Willi syndrome

Osteogenesis imperfecta type IV

Transverse myelitis

Primary pigmented nodular

Tuberous sclerosis, type 2

adrenocortical disease

Ventricular fibrillation, idiopathic

Seow Najjar syndrome

Wilson disease

Spastic paraplegia 14

Zygomycosis

Thickened earlobes with conductive
deafness from incus-stapes
abnormalities
Tremor hereditary essential, 2

The FDA orphan drug designations and approvals database was used to collect the
total number of orphan drug approvals per disease.21 Diseases with an approved orphan
product are more likely to be the focus of research studies and have a more clearly
defined patient population due to the clinical trial process. If a disease did not have an
orphan drug approval, but had an orphan drug designation, that was noted. There is a
substantial interest in cancer research and care infrastructure.85 Rare cancers may benefit
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from more accessible treatment centers for both patient information and the collection of
data. Diseases with orphan drugs and rare cancers have the potential for additional
information and interest, purposeful sampling was employed to investigate these
differences.86 The sample size allowed for a feasible investigation into data source quality
and infrastructure for rare disease prevalence.
Data sources and searches for evaluating quality of existing prevalence estimates
The Cleveland model of the healthcare environment81 demonstrates the interplay
between information and the consumers, clinicians, and researchers who utilize and
generate the data. The data sources for existing prevalence estimates were evaluated
based on the standards outlined by Silberg, Lundberg, and Musacchio.87 This framework
provides principles to evaluate the credibility and usefulness of health data. The four
areas are authorship, attribution, disclosure, and currency. Authorship refers to disclosing
the affiliations and credentials of authors and contributors. Attribution is clearly
displaying references and sources for all content. Disclosure is the ownership of the
website, including any commercial funding and conflicts of interest. Currency is the date
that content was posted and updated; for the purpose of this study it will be referred to as
date. Disclosure was evaluated at the website level and the other areas were assessed at
the article or webpage level for individual disease listings.
Eight rare disease, genetic disease, or health information websites were identified
prior to conducting the study as resources that researchers, patients, or medical
professionals in the U.S. might access for rare disease information. GARD, Orphanet,
and NORD are established rare disease specific resources. Genetics Home Reference,
GeneReviews, and OMIM provide information on genetic based conditions, which
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represent an estimated 80% of rare diseases. Medscape is a popular source for disease
information and is routinely included as a data source in previous studies that evaluated
internet based health information.78,88 SEER provides a query function on their website to
provide cancer statistics based on collected registry information. Descriptions of these
data sources and the sources’ disclosure information are listed in Table 2. These sites
were used to determine if information about the disease was available and if a prevalence
estimate was available.
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Table 2: Data sources for prevalence searches for data quality information and infrastructure assessment
Searches were conducted for two purposes: to evaluate data quality of existing prevalence estimates and to determine the
infrastructure for future estimates. This chart provides the data source, a short description from the source’s website, the financial
disclosure for their funding, and if it was used for data quality or infrastructure.
Data source

Description

Disclosure

Used for
Data
Infrastructure
quality
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Genetic and Rare Diseases
Information Center
(GARD), National Center
for Advancing Translational
Sciences (NCATS)

Provides the public with access to
current, reliable, and easy-tounderstand information about rare
or genetic diseases

Funded by two parts of the National Institutes
of Health: NCATS and the National Human
Genome Research Institute (NHGRI)

X

Orphanet

Portal for rare diseases that
includes an encyclopedia of rare
diseases and associated genes

Funded by Inserm, the French Directorate
General for Health, and the European
Commission through OrphaNetWork, a
Direct Grant of the 3rd Health Programme of
the European Union

X

Genetics Home Reference,
U.S. National Library of
Medicine

A consumer health website from
the National Library of Medicine,
which provides information for the
general public about the effects of
genetic variation on human health

Funded by the U.S. Government

X

GeneReviews, National
Center for Biotechnology
Information

Provides clinically relevant and
medically actionable information
for inherited conditions

Funded by the government through the
National Institutes of Health and chapters are
owned by the University of Washington

X
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Rare Disease Database,
National Organization for
Rare Disorders (NORD)

Provides brief introductions for
patients and caregivers to specific
rare diseases

Primary sources of funding are grants,
contracts, contributions, and an annual fundraising event; enhancements to the Rare
Disease Database were made possible
through a grant from the Anthem Foundation

X

Online Mendelian
Inheritance in Man (OMIM)

Documents genetic defects by
identified human genes when
available or genetic phenotypes as
a proxy

Funded by a grant from the National Human
Genome Research Institute and individual
donors; Initial development was supported by
Johns Hopkins Medicine and a grant from the
Maryland Department of Health and Mental
Hygiene

X

Medscape

Website providing physicians and
healthcare professionals medical
news, point-of-care drug and
disease information, and relevant
professional education and CME

Revenue is generated through the sale of
various types of advertising and sponsorship
products which include: pharmaceutical,
biotechnology and medical device
companies; hospitals and other healthcare
services companies; health insurance
providers; companies whose products or
services relate to health, wellness, diet,
fitness, lifestyle, safety and illness
prevention; and various other businesses,
organizations and governmental entities.
Advertisements are guided by posted policies.

X

Surveillance, Epidemiology,
and End Results Program
(SEER), National Cancer
Institute

Provides information on cancer
statistics in an effort to reduce the
cancer burden among the U.S.
population.

Supported by the Surveillance Research
Program in National Cancer Institute's
Division of Cancer Control and Population
Sciences

X

X

ClinicalTrials.gov is a database of
privately and publicly funded
clinical studies conducted around
the world.

Funded through the Department of Health
and Human Services

X

ICD-10 and ICD-11

Foundation for the identification
of health trends and statistics
globally, and the international
standard for reporting diseases and
health conditions. It is the
diagnostic classification standard
for all clinical and research
purposes. ICD defines the universe
of diseases, disorders, injuries and
other related health conditions,
listed in a comprehensive,
hierarchical fashion

Developed and distributed by World Health
Organization (WHO) globally and adapted in
the United States by the Centers for Medicare
and Medicaid Services (CMS) and the
National Center for Health Statistics (NCHS)

X

National Notifiable Disease
Surveillance System
(NNDSS)

Helps public health monitor,
control, and prevent a sample of
diseases including infectious
diseases such as Zika and
foodborne outbreaks, and
noninfectious conditions such as
lead poisoning

Funded by the U.S. Government

X

Recommended Uniform
Screening Panel

List of disorders that the Secretary
of the Department of Health and
Human Services recommends for
states to screen as part of their
state universal newborn screening
programs

Funded by the U.S. Government

X
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Clinicaltrials.gov

Google

Search engine

Publicly traded company, funded through ad
revenues

The National Library of
Medicine’s full-text repository of
life sciences journal literature

U.S government agencies and private
investors

Disease

X

X

Disease + Organization
Disease + Registry
Disease + Medical
Center
Pubmed
Disease
Disease + [Incidence
OR Prevalence]

X
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Searches were conducted using both the primary disease name and any additional
synonym names listed in GARD. Google searches were conducted for the disease name
and the disease name and “organization”, “registry”, or “medical center”. If any of the
searches resulted in a resource that listed the disease on the website or in the mission
statement, it was recorded. Some medical centers publish disease encyclopedias from
third party providers; these sources were not included to limit the over representation of
available data sources. Organizations, registries, and medical centers were included if
they were physically located in the U.S. or had a global organizational reach. It was noted
if the disease was listed under a broader umbrella disease or a more specific sub-type of
the condition. Two name variables were created; if the disease was listed under a broader
name on any of the health information websites and if the disease was listed under a more
specific name on any of the health information websites.
The data availability variables included if the disease was listed on each of the
health information website. Prevalence variables included if an estimate was available
and the quality estimates of authorship, attribution, and date. The total number of
available prevalence estimates and the total number of available prevalence estimates
with all three quality factors were also reported. Initial disease searches were conducted
between June 4 and August 21, 2018.
Infrastructure for establishing disease prevalence estimates
Building off Cleveland’s model of the healthcare environment, infrastructure can
be described as the interplay between information and technology. Prevalence
information can only be collected or evaluated if technologies and systems are in place.
Seven data sources were identified as indicators of prevalence infrastructure. In this
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paper, prevalence infrastructure refers to the organizations, technology, or data sources
that provide capacity to provide prevalence estimates. The availability of an ICD code
was evaluated for the current ICD-1063 system and the working list for ICD-11.89 Disease
inclusion in the ICD system was coded as not available or a specific disease code exists.
Two registries were included in the sample the National Notifiable Disease Surveillance
System (NNDSS) and SEER, a national cancer registry. The Recommended Uniform
Screening Panel was also reviewed to see if any of the diseases in the sample are
recommended for newborn screening.
For searches conducted on Clinicaltrials.gov the total number of search results
and the number of trials that were considered active were recorded. 90 A trial was
considered active if it was currently listed as not yet recruiting, recruiting, enrolling by
invitation, or active not recruiting. Clinical trials indicate the current level of
governmental and industry investment and interest in a particular disease and the
opportunity to collect prevalence information.
A Pubmed search was conducted for each disease using the primary and any
secondary disease names. An additional search using the disease names and “incidence”
or “prevalence” was also conducted. The number of results were recorded. The purpose
of conducting these searches was to see the depth of published knowledge on the disease
and to provide an indication of the academic and clinical interest in the disease as is
represented by the research and clinical practice components of the model of the
healthcare environment. The individual studies were not evaluated as the goal was not to
determine a specific prevalence for each disease, but to assess what information is
currently accessible and the potential for future validation of prevalence estimates. The
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web sources included in the study routinely synthesize and report the key information
from academic studies as part of disease listings. Reporting the number of PubMed
results provides an indication of the any recent findings that may inform reported disease
estimates in the future. Finally, during the previously described google searches, the total
number of organizations, disease specific organizations, registries, and medical centers
were recorded. If a disease had an organization that designated medical centers that was
also recorded.
Data analysis
Data analysis was conducted in Stata version 13.1. Descriptive statistics were
calculated and recorded for data quality and infrastructure variables. This included
frequency counts for categorical data and the mean, standard deviation for continuous
variables. Means, standard deviation, and p-values were reported. None of the variables
were found to be normally distributed, so non-parametric statistics were used. Results
were considered statistically significant at p=.05.
Chi-squared tests were conducted to compare the statistical significance of the
availability of the disease appearing on each health website by group. Simple logistic
regression was conducted on both name variables; disease listed under a broader name
and disease listed under a more specific name. Simple logistic regression was also
conducted for the availability of a prevalence estimate in each health information
website. (Table 5) The dependent variables were orphan drug, rare cancer, and an
interaction variable for rare cancer and orphan drugs. Shapiro-Wilk tests were conducted
to determine if the residuals were normally distributed. F-tests were conducted to make
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additional comparisons by group. The logistic regression results are presented in the
appendix.
𝑦 = 𝛽0 + 𝛽1 𝑟𝑎𝑟𝑒𝑐𝑎𝑛𝑐𝑒𝑟 + 𝛽2 𝑜𝑟𝑝ℎ𝑎𝑛𝑑𝑟𝑢𝑔 + 𝛽3 𝑟𝑎𝑟𝑒𝑐𝑎𝑛𝑐𝑒𝑟 ∗ 𝑜𝑟𝑝ℎ𝑎𝑛𝑑𝑟𝑢𝑔 + 𝜀
Simple linear regression and follow-up Shapiro-Wilk and F-tests were conducted
at the disease level for the average number of prevalence estimates available and the
average number of quality prevalence estimates. Simple linear regression and the followup tests were also conducted to investigate the impact of having an orphan drug and
being a rare cancer for each of the quality indicators (author, date, and attribution) and for
having all quality estimates. Means, standard deviation, and p-values were reported.
(Table 5)
Chi-squared analysis was conducted to compare the number of quality estimates
by group according to the sector of the location for the estimate. The different sectors
were government funded, industry or private funding, medical center or professional
society, and organization. (Table 6)
Simple logistic regression was conducted for each independent infrastructure
variable with the dependent variables rare cancer, orphan drug, and the interaction
variable. These variables included if each disease had an organization, a disease specific
organization, a registry, a medical center, an organization that designates medical centers,
an ICD-10 specific code, and an ICD-11 specific code. (Table 7) Follow-up ShapiroWilks and F-tests were conducted and the individual linear regression results are
presented in the appendix.
Simple linear regression for continuous infrastructure variables and follow-up
tests were conducted for the number of organizations, the number of medical centers, the
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number of clinical trials, the number of active clinical trials, the number of PubMed
disease results, and the number of PubMed incidence or prevalence results.
Results
Disease sample characteristics
Of the 80 sample diseases, 70 included information about therapeutic category in
GARD. (Table 3) Additional information about disease characteristics were not captured.
Most diseases (38%) had one therapeutic category listed and 15 diseases (18.8%) had
two. Ten of the diseases (12.5%) did not have any information listed about their
therapeutic category. Von Hippel-Lindau disease (group 3) had the most identified with 8
listed. The therapeutic category with the most disease representation in the sample were
congenital and genetic diseases (39%), with nervous system (20%), blood diseases
(13%), and eye diseases (13%).
Table 3: Therapeutic categories for sample diseases
Category
Rare Cancer
Congenital and Genetic Diseases
Nervous System Diseases
Blood Diseases
Eye diseases
Not Listed
Metabolic disorders
Skin Diseases
Digestive Diseases
Endocrine Diseases
Immune System Diseases
Kidney and Urinary Diseases
Musculoskeletal Diseases
Newborn screening
Reproductive Diseases
Hereditary Cancer Syndromes
Mouth Diseases
Viral infections

Total
40
32
16
10
10
10
9
7
6
6
4
4
4
4
4
3
2
2
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Autoimmune / Autoinflammatory diseases
Ear, Nose, and Throat Diseases
Fungal infections
Parasitic diseases

1
1
1
1

Of the diseases in the sample that had at least one approved orphan drug, 65% had
more than one drug approval. There was a statistically significant difference (p=.036) in
the average number of orphan drugs if the disease was a rare cancer (mean=2.9)
compared to the number of orphan drugs if a disease was not cancer (mean=1.25). Acute
lymphoblastic leukemia (ALL) (group 1), had the greatest number of orphan drug
approvals with 13. Four diseases had an orphan drug designation, but the drugs had not
been approved by the FDA. Of these, 3 were rare cancers.
Available prevalence estimates and data quality
Four of the diseases were only identified on the GARD list and could not be
found in any other data source, these diseases were all in group 4. This difference was
found to be statistically significant by group (p=.006), orphan drug, and rare cancer status
(both p=.04). Orphanet included the greatest number of the diseases (78%) followed by
OMIM (71%), Medscape (53%), NORD (39%), Genetic Home Reference (36%), and
Gene Reviews (19%).
Of the diseases included in the sample, 13 (16.25%) were listed under a more
specific name and 27 (33.8%) were listed under a broader disease name on at least one of
the health information websites. For example, in GARD the disease chosen for the
sample was “transverse myelitis”, but in Orphanet a more specific name included two
additional subtypes and a listing for acute transverse myelitis. Spastic paraplegia 14 was
listed under the broader “spastic paraplegia” everywhere except GARD. One disease per
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group was listed by both a broader and more specific disease name in different sources.
OMIM had the most diseases (9) listed under a more specific disease name and Medscape
listed the most diseases under a broader disease name (13). Orphan drug and rare cancer
were not statistically significant factors for being listed under another name. (Table 4)
Table 4: Disease name conventions and data websites with prevalence estimates by
group
The coefficients, standard error, and statistical significance for individual logistic
regression results can be found in Appendix A-B.

Broader
name
More specific
name
GARD
NORD
Orphanet

Group 1
(OD,
RC)

Group 2
(OD,
no RC)

Group 3
(no OD,
RC)

Group 4
(no OD,
no RC)

Total

n=20
n (%)

n=20
n (%)

n=20
n (%)

n=20
n (%)

n=80
n (%)

7 (35)

9 (45)

7 (35)

4 (20)

27 (33.8)

None

6 (30)

5 (25)

1 (5)

1 (5)

13 (16.3)

None

2 (10)

2 (10)

3(15)

1 (5)

8 (10)

4 (20)
8 (40)

10 (50)
12 (60)

5 (25)
10 (50)

1 (5)
8 (40)

20 (25)
38 (47.5)

2 (10)
0 (0)

10 (50)
4 (20)

5 (25)
4 (20)

2 (10)
1 (5)

19 (23.8)
9 (11.3)

12 (60)
3(15)

9 (45)
8 (40)

4 (20)
2 (10)

3 (15)
0 (0)

28 (35)
13 (16.3)

Genetics
home
reference
GeneReviews
Medscape
OMIM

Factors and
differences in
groups that are
statistically
significant

None
Group 3 vs. Group
4
None
Group 3 vs. Group
4; Group 1 vs.
Group 2;
Group 1 vs.
Group 3
None
Group 3 vs. Group
4;
Group 1 vs. Group
2
None

Orphanet included prevalence estimates for the diseases studied more frequently
than any other source (47.5%) followed by Medscape (35%) and NORD (25%). (Table 4)
GARD only listed prevalence estimates for 10% of the diseases. The difference in the
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number of prevalence estimates available was statistically significant by orphan drug
status for NORD, Genetics Home Reference, and Medscape. Rare cancer status was not a
statistically significant predictor of having a prevalence estimate listed on any of the sites.
OMIM provided information about known case studies for an additional 24 conditions.
Of the diseases, 75% had a prevalence estimate listed in at least one of the data sources.
Of the diseases that had an estimate, 46.78% of the diseases had the same estimate listed
in multiple places.
There were a total of 443 prevalence estimates for diseases in the sample, 361 for
rare cancers and 262 estimates for diseases with an orphan drug. Diseases with an orphan
drug had an average of 9.03 available prevalence estimates and 2.05 estimates with all
three quality factors, while diseases without an orphan drug had an average of 2.05
disease estimates and .575 quality estimates. Rare cancers had an average of 6.55
prevalence estimates and 1.73 quality estimates, compared to non-cancers which had 4.53
average estimates and .9 quality estimates. Diseases with an orphan drug that were cancer
had an average of 9.8 estimates compared to diseases without a drug that were not rare
cancer that had an average of .8 estimates. (Table 5) Having an orphan drug was a
statistically significant factor for both having a prevalence estimate and having a quality
prevalence estimate.
Of the 443 total prevalence estimates available for any of the sample diseases,
only 106 (23.93%) had all three quality indicators. (Table 5) Of the estimates, 47.4% had
attribution, 45.4% had date, and 32.7% listed authorship. Of the estimates that had
attribution, 30.5% of them only included the name of the original source for the content
and not specific data source, dates, or authorship for the source content. For the author,
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9.7% of estimates provided an organizational editorial board for the author, but did not
identify a specific person who was responsible for the content. Including a date was
statistically significant by rare cancer status. Within the estimates, there was no
statistically significant difference in having all three quality factors by orphan drug or
rare cancer status.
Table 5: Prevalence estimates with data quality factors
The coefficients, standard error, and statistical significance for individual logistic or
linear regression results can be found in Appendix C-D.

By disease

Average
number of
estimates
Average
estimates
with all
quality
factors
By estimate

Author

Group 1
(OD, RC)
n=20
m (std)

9.8 (9.82)

2.5 (2.59)
n=196
n (%)
61 (31.12)

Group 2
(OD, no RC)
n=20
m (std)

Group 3
(no OD,
RC)
n=20
m (std)

8.25 (8.95) 3.3 (4.27)

1.6
(1.50) .95 (1.50)
n=165
n=66
n (%)
n (%)
31
45 (27.27)
(46.97)

Date

85 (43.37)

60 (36.36)

Attribution
All quality
factors

99 (50.51)

67 (40.61)

50 (25.51)

32 (19.39)

45
(68.18)
37
(56.06)
20
(30.30)

38

Group 4
(no OD,
no RC)
n=20
m (std)

.8
(1.01)

Total
n=80
m (std)

5.54
(7.78)

.2
1.31
(.52)
(1.87)
n=16
n=443
n (%)
n (%)
8
145
(50) (32.73)

11
(68.75)
7 (43.75)
4
(25)

201
(45.37)
210
(47.40)
106
(23.93)

Factors and
differences in
groups that
are statistically
significant

Group 3 vs.
Group 4; Group
1 vs. Group 2
(therefore
orphan drug)
Group 3 vs.
Group 4; Group
1 vs. Group 2
(therefore
orphan drug)

None
Group 2 vs.
Group 4;
Group 1 vs.
Group 3
(therefore
cancer)
None
None

Of the estimates, 39.3% were listed on a medical center’s website and 31.4% were
listed on government funded sites or data sources (including Orphanet). (Table 6)
Orphanet was the source with the single highest number of estimates, 38. Estimates
posted on industry or privately funded sites had the highest percentage of including all
three quality factors (64.3%). Government funded websites had the highest number of
quality estimates, but this represented only 38.9% of the estimates available on these
sites. Only one estimate (.57%) listed on a medical center website included all three
quality factors.
Table 6: Sector for estimates by orphan drug, rare cancer, and data quality status

Group 1
(OD, RC)
n=196
n (%)
Government
funded

Group 2
(OD, no
RC)
n=165
n (%)

Group 3
(no OD,
RC)
n=66
n (%)

Group 4
(no OD,
no RC)
n=16
n (%)

Total
n=443
n (%)

Total
with
quality
n=106
n (%)

52 (26.53)

40
(24.24)

34
(51.52)

13
(81.25)

139
(31.38)

54 (38.9)

Industry or private
funding
Medical center or
professional
society

14
(7.14)

22
(13.33)

5
(7.58)

1
(6.25)

42
(9.48)

27 (64.3)

97
(49.49)

63
(38.18)

13
(19.70)

1
(6.25)

174
(39.28)

1
(.57)

Organization

33
(16.84)

40
(24.24)

14
(21.21)

1
(6.25)

88
(19.86)

24
(27.27)

Infrastructure for prevalence estimates
Having an orphan drug was a statistically significant predictor of having an
organization, medical center, registry, ICD-10, and ICD-11 specific code. (Table 6) A
total of 50 (62.5%) diseases had at least one patient organization. On average there were
3.1 organizations per disease. (Table 7) Neuroblastoma (group 1, cancer and has an
orphan drug) had the most organizational representation with 19 organizations. Being a
rare cancer was a statistically significant factor in the likelihood of the disease having an
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organization. Only four the diseases in group 4, not cancer and no orphan drug, had
organizational representation. Disease specific registries were available for 19 diseases.
Medical centers were identified for 56 (70%) of the diseases. Testicular cancer (group 1)
had the most identified medical centers with 96. Seven of the diseases had an
organization that designates medical centers of excellence for the disease of interest.
Only 19 diseases (23.75%) had an ICD-10 specific code and 43 diseases had an ICD-11
specific code (54%).
The total number of diseases listed in the SEER Coding and Staging Manual was
not statistically significant by orphan drug status (p=.677). None of the diseases in the
sample were included in the NNDSS system. One disease, methylmalonic acidemia with
homocystinuria (group 2), was listed as a secondary condition in the Recommended
Uniform Screening Panel (RUSP) for newborn screening.
Table 7: Prevalence infrastructure by group
The coefficients, standard error, and statistical significance for individual logistic
regression results can be found in Appendix E.
Group 1
(OD,
RC)

Group 2
(OD,
no RC)

Group 3
(no OD,
RC)

Group 4
(no OD,
no RC)

Total

n=20
n (%)

n=20
n (%)

n=20
n (%)

n=20
n (%)

n=80
n (%)

Factors and
differences in
groups that
are
statistically
significant

17 (85)

17 (85)

12 (60)

4 (20)

Group 2 vs.
Group 4; Group
50 (63) 3 vs. Group 4

A disease specific
organization exists

6 (30)

10 (50)

5 (25)

2 (10)

23 (29)

A registry exists

4 (20)

11 (55)

3 (15)

1 (5)

Organization
exists for disease
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Group 3 vs.
Group 4
Group 3 vs.
Group 4; Group
19 (24) 1 vs. Group 3

A medical center
exists

17 (85)

17 (85)

14 (70)

8 (40)

ICD-10 Specific

7 (35)

8 (40)

3 (15)

1 (5)

ICD-11 Specific

14 (70)

14 (70)

5 (25)

3 (15)

Group 3 vs.
Group 4
Group 3 vs.
Group 4
Group 3 vs.
Group 4; Group
36 (45) 1 vs. Group 2
56 (70)
19
(23.75)

Table 8: Continuous prevalence infrastructure components by group
The coefficients, standard error, and statistical significance for individual linear
regression results can be found in Appendix F.

Number of
organizations

Group 1
(OD,
RC)

Group 2
(OD,
no RC)

Group 3
(no OD,
RC)

Group 4
(no OD,
no RC)

Total

n=20
m (std)

n=20
m (std)

n=20
m (std)

n=20
m (std)

n=80
m (std)

5.5
(4.81)

4.45
(4.31)

2.1
(2.65)

0.25
(.55)

3.075
(4.0)

30.95
(25.20)

16.85
(23.91)

8.65
(13.61)

1.5
(3.68)

14.49
(21.4)

Number of
clinical trials

341.35
(518.49)

26.45
(39.33)

41.9
(115.73)

.9
(1.77)

102.65
(296.1)

Number of
active
clinical trials

102.85
(151.56)

8.45
(12.68)

11.4
(29.52)

.25
(.55)

30.74
(86.9)

7834.15
2479.25
1046.2
(9905.07) (3876.32) (1451.33)

425.1
(834.99)

2946.18
(6042.4)

41.7
(120.18)

234.31
(444.1)

Number of
medical
centers

PubMed
disease
results
PubMed
incidence or
prevalence
results

626.65
(680.34)

142.15
(192.39)

126.75
(289.28)

Factors and
differences in
groups that are
statistically
significant
Group 3 vs. Group
4;
Group 1 vs. Group
2
Group 3 vs. Group
4; Group 1 vs.
Group 2; Group 1
vs. Group 3
Group 1 vs. Group
3;
Group 1 vs. Group
2
Group 1 vs. Group
3;
Group 1 vs. Group
2
Group 1 vs. Group
3;
Group 1 vs. Group
2
Group 1 vs. Group
3;
Group 1 vs. Group
2

The average number of PubMed search results per disease were 7,834 for Group 1
compared to 425 for group 4. Nueroblastoma (group 1) had the highest number of total
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PubMed results with 38,880 and Acute lymphoblastic leukemia (ALL) (group 1) had the
highest number of search results for incidence or prevalence data in PubMed (2,510).
There was a statistically significant difference in the number of PubMed results when
comparing Group 1 with either Group 3 or Group 2. One disease, Hutterite
cerebroosteonephrodysplasia syndrome (group 4), had no results and 7 diseases did not
have any search results for incidence or prevalence data in PubMed.
There were clinical trials registered for 71.25% of the diseases and active clinical
trials for 60% of the diseases. (Table 7) The average number of active clinical trials for
diseases with an orphan drug were 55.65 compared to 5.83 for diseases without an orphan
drug, there were statistically significant differences between diseases in Group 1 and
those in Group 3 or Group 2. (Table 8) Only 4 diseases in Group 4 had active clinical
trials, while there were 19 (95%) in Group 1.
Discussion
The Cleveland model of the healthcare environment details the relationship
between patients, clinical practice, and research to both inform and utilize information
and technology.81 For rare diseases this interplay provides context for the availability of
prevalence information and the related challenges of rare disease knowledge and data
quality. However, the data quality of that information is not meeting core standards of
data information.87 Overall, few rare diseases report the data sources used to establish
prevalence. Diseases that have an orphan drug are statistically more likely to have
infrastructure in the form of organizations, identified medical centers, registries, or ICD11 specific codes to establish prevalence estimates in the future. An orphan drug approval
can serve as a catalyst for increased medical knowledge and prevalence infrastructure.
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Rare cancer was not seen to be a statistically significant factor in information availability,
quality, or infrastructure. Our methods to establish prevalence through registries, claims
data, or other methods require a substantial investment of resources and are not always
reliable without a substantial sample size, a clear disease definition, and a significant
investment of resources,33,35,70–73,91 qualities many rare diseases do not exhibit.
Limitations
It is possible that the total prevalence of a disease is a confounding factor for the
availability of information. For example, the identification of 500 cases of an emerging
disease might result in more attention and opportunities for further investigation
compared to a disease with only 50 identified cases. This study was meant to assess what
we know about the prevalence of rare diseases or how we can ascertain this information,
but the number of people impacted is likely a contributing factor to what is known. It
would have been difficult to control for prevalence, based on the limited available
information. This both contributes to the problem and highlights the need for the study.
It was not possible to complete searches for all 6,500 rare diseases; a sample of 80
rare diseases was chosen to allow for representation and analysis that would allow for
informed comparisons by group, rare cancer, and orphan drug status. The sample did not
control for disease diversity beyond the status of having an orphan drug or being a rare
cancer. The overall heterogeneity of rare diseases made it difficult to account for the
many potential factors that could be relevant in available prevalence information.
Age of onset and therapeutic category are two areas that could be confounding
factors within the results. If some therapeutic categories have more rare diseases, the
specialists and researchers in those areas may have developed increased strategies for
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diagnosis, tracking, and patient support. Age of onset could impact prevalence estimates
or infrastructure due to an increased concern about pediatric conditions and the loss of
life due to early mortality. Therefore, diseases with pediatric onset may have a
disproportionate level of infrastructure compared to later onset diseases. Ethical
considerations for testing therapies for childhood diseases may mean that there are fewer
orphan drugs for childhood diseases. Information about the breakdown of therapeutic
categories for all rare diseases or differences based on age of onset are not available and
could not be controlled for the purpose of this study.
The disease sample disproportionately included melanomas; 3% of rare cancers
on the GARD list and 12% of cancers with an orphan drug are melanomas. In this study,
25% of rare cancers with an orphan drug are melanomas. Despite these sample
limitations, the sample size is believed to be adequate to assess the current state of
available infrastructure and to guide for future investigations or policy considerations.
The identification of the GARD list of rare diseases to generate the sample was
based on GARD’s status as one of the authoritative resources and leaders for rare disease
information in the U.S. The list included diseases that were difficult to identify in other
sources as the listing sometimes only included the name without a disease description.
For example, one of the sample diseases was Renal cell carcinoma 4. There was no
description of the disease listed in the GARD database, therefore it was difficult to
determine if this was Stage 4 or Type 4. The GARD list also may have had duplication
beyond what was indicated. In a few cases, other data sources indicated that a disease
synonym existed, but in GARD that term had its own listing, indicating a unique
condition. It is possible that the listed term was outdated and the records were describing
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the same condition or that there is not scientific consensus on the disease definition. This
could result in misclassification of the overall availability of information for the disease.
This inconsistency is a valuable finding in understanding how we should approach the
dissemination of rare disease information in the future and the challenges individuals face
when searching for high-quality information.
There is also the potential of disease misclassification into the wrong group. For
example, on the GARD website, “melanoma astrocytoma syndrome” is listed as having
an approved drug, Aldesleukin92. However, the website for this condition states that it is
“indicated for the treatment of adults with metastatic renal cell carcinoma (mRCC) or
metastatic melanoma (mM)” and neither the prescribing information nor the drug website
specifically mention “melanoma astrocytoma syndrome”. It is possible that the drug
treats all forms of melanoma, that it is used off-label, or that this syndrome is not well
defined. Either way, the current information brings up questions related to how we name,
classify, and describe diseases.
Some of the diseases included on the list were “familial” versions of other
conditions, such as “familial pancreatic cancer”. The distinction of a familial form of the
condition has clinical importance for the risk of inheritance of the disease, but is difficult
to differentiate in most data sources and requires family history in addition to an
individual’s medical records.93,94 Familial diseases were considered distinct forms of the
disease for the purpose of this study, but there are inconsistencies related to the
importance of that distinction across data sources and in practice.
Systematized Nomenclature of Medicine- Clinical Terminology (SNOMED) is
the clinical healthcare terminology system used in many electronic health records.57
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SNOMED can capture clinical observations and was established to integrate with ICD-10
codes as part of the electronic health record systems.95 SNOMED nomenclature and use
happens largely behind the scenes in most electronic health records systems. Despite
SNOMED being included in other studies to evaluate coding language for rare diseases, it
was not included in this study as it is not extensively used for research purposes in the
U.S. as most methodologies rely on ICD codes.80
The number of PubMed search results could be skewed by additional factors such
as diseases that had an animal form. It is also possible that a study had the primary goal
of estimating the total number of people impacted by the disease, but it did not appear in
the “incidence or prevalence” search. PubMed searches were meant to serve as indicator
variables for the extent of scientific interest and current investment in the disease and the
impact is likely minimal.
U.S. based clinical trials are required to be submitted and listed on
ClinicialTrials.gov if the study purpose is to evaluate a drug, biologic or device.96
Researchers can voluntarily submit their study if they are investigating other methods,
but investigators conducting observational studies are not required to do so. Therefore, it
is likely that diseases that have an orphan product approval in the U.S. would have had a
study that was required to be posted on the site. The use of actively recruiting or on-going
studies is a more accurate indicator of current or future research investment.
Data quality was assessed using a widely cited set of principles.87 Some of the
disease estimates were identified as having attribution, but the listed information only
provided an organization source, such as the American Cancer Society or Orphanet. The
same disease estimate in those data sources may not have included attribution or the
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listed author was only at the organizational level, such as a medical advisory board for
the organization. This would make it difficult to trace the data estimate to the original
source. The author or attributed sources were often trusted organizations who would have
access to expert reviewers, but it may misrepresent the reader’s ability to accurately
identify how estimates were determined. Authors were listed at an organizational level
for 9% of the estimates and 30% for the attribution of estimates. The majority of these
estimates were missing one of the other two data quality measures, limiting the overall
impact of misclassification of the estimate as high-quality data.
Identifying specific rare diseases in data sources
Identifying a disease across case studies and in medical terminologies is critical to
advancing research. The importance of consistent identification and naming conventions
for rare diseases has led to the establishment of collaborations such as the Monarch
Initiative and IRDiRC to map terminologies across resource sites and to accelerate
translational research.60,97,98 Some data sources, such as Orphanet, provide the known
linked identifiers from a variety of places, including OMIM, ICD-10, and GARD.
However, other resources are more isolated in the information that they provide, which
makes it more difficult to track diseases with less information across data sources.
Although NIH collaborates on many of the international initiatives, the data resource list
does not currently reflect some of the on-going international efforts to improve naming
conventions, such as providing the identifier for other sources.
Personalized medicine and a trend towards common diseases being
subcategorized into distinct disorders are also impacting the healthcare landscape.17,28,38
The increase in genetic testing is changing the information that is available to patients99
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and the types of treatments that are in development.17 In 2010, an estimated 10% of FDA
approved drugs contained pharmacogenomic information.77 Targeted drugs have the
potential to result in fewer adverse events and decrease healthcare costs.100–102 This
approach requires clinically validated biomarkers and evidence that the resulting
treatment is effective, safe, and more cost-effective than drugs already on the market.
Understanding the relationship between prevalence, personalized medicine, and drug
incentives will be necessary to prepare for costs and potential inequities in our healthcare
system. As our ability to pinpoint genetic variations of diseases increases, we will need to
find ways to provide information on these differences to clinicians and patients. Our
infrastructure to identify and treat these patients may not be ready for these types of
advances. This may to lead to increased inequities based on patient characteristics and the
ability to access to elite providers.
Beyond genetic variation, multiple diseases in the sample were listed under a
broader umbrella term in both NORD (6.25%) and Medscape (23.75%). Grouping
diseases under umbrella terms is useful for pooling resources and sharing medical
advances; rare diseases have even been credited with providing medical insights for
related common conditions.91,103 However, evidence indicates that small differences in
cancer type and location can impact prognosis17 and the increasing use of genetic data for
biologics101 necessitates specificity. Understanding the differences between diseases
within an umbrella grouping can impact treatment effectiveness and health outcomes.
There is also a statistically significant difference in the likelihood of being listed under a
more specific name according to the presence of an orphan drug, which may indicate
some of the ways drug companies access the incentives of the ODA.
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The importance of this consistency and ability to follow the depth of current
medical knowledge may not be necessary to the average medical consumer. However,
many rare disease patients and caregivers express the need to become experts in their
disease due to the limited information and knowledge among many health experts.7,104,105
Many rare disease patient organizations, which are often founded by caregivers, become
the driving force behind research and product innovation.106–110 Finding ways to link data
across information sources becomes necessary to ensure that clinicians writing case
studies, researchers conducting studies, and patients establishing organizations can work
together to identify advances.
Prevalence data quality
Statistical analysis for prevalence requires knowledge about the anticipated size of
the population, for small populations these variations can impact the accuracy of
prevalence calculations.25,37 The need for baseline information and an ability to identify
the source of these estimates is a necessity for data integrity. Data sources, even trusted
sources such as medical centers and government websites do not always provide the
information needed for individuals to assess the quality or relevance of the data. In the
Google searches for centers and organizations estimates for diseases were often posted
without any reference to the data source for the estimate. Often, these estimates were
consistent across multiple sites, without attribution.
Industry had the most complete data quality information (64% of estimates)
compared to any other source. This may be attributed to the fact that they are less likely
to have implicit trust from consumers. It should be concerning that only 1 estimate
available on a medical center website had all three data quality factors. Health websites
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should provide the information necessary for individuals to find the original source of the
information to allow them to critically assess the information and current scientific
knowledge.
The primary audience of interest for health websites informs the content and
depth of technical language. The funding source may also impact the type of content
displayed and the date of updates. NORD, Genetic Home Reference, and Medscape were
the sites with a statistically significant difference in posted information by orphan drug
status. OMIM only had two prevalence estimates for diseases without an orphan drug.
The listings in OMIM are often the synthesis of other published studies to identify and
link information about genes and disease phenotypes, which could explain why diseases
with less published data from other sources are unlikely to appear in this data source.
Some of the entries in NORD’s Rare Disease Database are provided through educational
grants from pharmaceutical companies or disease specific organizations.11 Similarly,
Medscape receives grants and advertising revenue.111 Both organizations have editorial
and conflict of interest policies on the content of articles, but the decision related to
which content is produced, is likely impacted by the availability of resources and easily
identifiable disease experts.
Keratoconus (Group 2) had the highest number of consistent estimates (19). Of
these, only 1 referenced the source of these estimates, a study published in 1986 that
found a total of 64 residents of Olmsted County, Minnesota were diagnosed between
1935 and 1982.112 Would we still consider these results generalizable to a modern US
population? More recent studies have been conducted internationally and indicated that
the impacted population may be larger than previously estimated.113 In the U.S., no
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additional prevalence studies have been conducted. The most recent orphan drug
designation was filed in 2017, indicating that pharmaceutical companies may still be able
to benefit from current prevalence estimates. However, by not investing in new estimates
we might be missing other key data trends such as disparities in who is impacted by the
condition or inequities in who is being diagnosed or treated. This condition has an
effective treatment, but for other conditions outdated statistics may represent missed
opportunities.
Infrastructure for prevalence estimates
The findings related to ICD-10 codes are consistent with similar investigations in
the literature.62,66 It is well documented that ICD-10 codes do not accurately capture rare
diseases. A disease with an approved orphan drug would necessitate a billing code for
submitting claims to the insurance company, therefore, it is not surprising that there was a
statistically significant difference based on orphan drug status for ICD-10 and ICD-11.
Rare disease patient organizations have a well-documented history of driving
change in the rare disease space and collaborating with the other stakeholders. However,
if a disease does not generate interest or support from beyond the identified population,
the organization may not be financially sustainable. Which may indicate why the
presence of an orphan drug impacts the likelihood that an organization for the disease
exists. Rare cancer status was a statistically significant indicator of having an available
patient organization, but not for the number of organizations. Many of the cancers
included in the study were found to be naturally grouped with other diseases or listed
under broader disease groupings. It is possible that rare cancers, despite being classified
as rare diseases, are viewed differently by patients, families, and the infrastructure that
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supports them. There may be a closer alignment to cancer, rare or common, then to rare
diseases. Many top selling orphan drugs are oncology drugs,19 and this study found a
relationship between rare cancer and a higher number of available orphan drugs.
Decisions to reinforce infrastructure and stimulate the investment in rare diseases, should
consider the goals and recognize the disparities in what is available based on disease and
therapeutic category.
Registries, organizations, and medical centers for rare cancers often did not
include the specific subtypes of the cancer included in the study. Oncologists may be
capturing this information, but it is not being reported in scientific and patient resources.
It is also possible that the federal investment in cancer infrastructure through SEER
changes the need for smaller registries to be established and maintained for individual
cancers. Registry data does not always include the detailed site and histology information
for rare cancers.46 Indicating a need for a better way to capture this information in the
future.
Having an orphan drug is a statistically significant factor for more infrastructure.
However, it is difficult to determine the direction of the relationship between
pharmaceutical interest and infrastructure. Four diseases had an orphan designation
without an FDA approval for any orphan drug. There was a statistically significant
difference (p=.0002) between the average number of prevalence estimates available for
diseases with an orphan designation (7.5) compared to diseases that did not have an
orphan drug designation (1.44). These diseases were not statistically more likely to have
an organization and only one of the four had an ICD-10 code. This could support a theory
that a disease needs some research or investment prior to attracting pharmaceutical
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investment and the additional infrastructure follows, potentially with pharmaceutical
support.
Policy implications
Rare disease patient organizations are an increasingly integral force in driving
research.35,106,108,109 Establishing systems that can provide higher quality raw data could
help drive other research goals; establishing natural history progression, investigating
disease risk, identifying treatment protocols, and developing treatments. The pace of
scientific advancement, especially in genetics, provides hope to many patients.56,102,114
There are international efforts underway to leverage these technologies by mapping
disease terminologies across data sources97,98 and establishing prevalence estimates.76 To
realize these benefits in the U.S., especially with the geographic diversity and inequitable
access to high quality healthcare, supportive infrastructure must be established to support
these efforts in a systematic way instead of a disease-by-disease approach.
When discussing the U.S. definition for rare diseases, it is important to
acknowledge that the current definition is a static prevalence. As the U.S. population
grows, the threshold for attaining rarity will become less inclusive over time, rather than
staying proportional to the population. In 1983, the year the Orphan Drug Act was
passed, the population of the U.S. was 233.8 million115, in 2019 the estimated population
was roughly 328.6 million116. In 1983, to be considered a rare disease it needed to impact
.086% of the population, whereas in 2018 a disease would need to impact .061% of the
population. Although this difference is currently minimal, over time, we must decide if
this metric needs to be reconsidered and if the definition itself can help us meet policy
and population health goals.
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As is outlined in the healthcare infrastructure model, the technological needs and
information are both being generated and demanded by consumers, researchers, and
clinicians simultaneously. This can occur as new conditions are being identified and
information is being collected across platforms. Disease experts and clinicians, guided by
patients, should drive infrastructure needs, instead of pharmaceutical companies. It is not
possible to ascertain the direction of the relationship between a disease having an orphan
drug and additional infrastructure. It is difficult to determine if a disease requires
infrastructure prior to attracting pharmaceutical interest or if a disease gains infrastructure
support based on pharmaceutical investment.
The heterogeneity of rare diseases and the size of the U.S. makes it unlikely that a
one-size fits all approach would adequately account for the diverse needs associated with
capturing, tracking, and estimating prevalence. Most rare diseases are unlikely to meet
the criteria needed to justify establishing a surveillance system.47 Under our current
system, organizations or medical centers are the most likely champions to represent a rare
disease and invest in registries or other disease specific structures. Ultimately,
pharmaceutical companies have an interest in prevalence, but not until they have a
product in development. Leveraging long-term pharmaceutical interest in prevalence
estimates may provide an opportunity to utilize some of the application fees for the FDA
approval process to establish a fund to conduct and validate rare disease prevalence
studies.
Entities that maintain their own tracking infrastructure such as registries should
investigate data sharing agreements with entities tracking the same diseases.39,58 Of
diseases that had at least one patient organization, 82% had more than one organization.
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This represents a splintering of resources and knowledge that could complicate the ability
to validate estimates. Medical centers may be able to attract patients if they establish
disease centers of excellence within their facility. Patient organizations have begun to
identify and designate these entities to provide patients with recommendations for where
to find disease experts. Patients who are not satisfied with care at their local medical
facilities may seek a specialized medical center. These centers will not be able to develop
in all geographic regions.
Clinicians are on the front line of disease tracking. Even if a patient seeks out a
patient organization and decides to independently join a registry, that would be based on
a diagnosis they received from a physician. Physicians are trained to look for the most
likely solution to a problem, “when you hear hoofbeats, think of horses not zebras”. If a
condition is only documented as impacting a handful of patients, it may be more difficult
for a medical professional to consider the possibility of the rare “zebra”, leaving patients
without a diagnosis or appropriate care. Diagnosis is a well-documented challenge for
rare disease patients, which may result in multiple interactions with the healthcare system
in multiple locations before an accurate diagnosis is achieved.28 Disease experts may be
outside of an individual’s geographic region65 and understanding care patterns is crucial
when assessing the limitations of using clinical data, especially if it is limited to one site
or database.73 Research is also reliant on collecting substantial evidence prior to
developing treatment guidelines, but understanding what is substantial must be based on
the estimated population. Payers may be reluctant to authorize experimental procedures
without clear medical guidelines, especially if the evidence is less robust then for a
common condition.

55

Researchers who investigate estimates are reliant on ICD codes to indicate a
specific condition or to sort through case notes and indicator codes to validate the
diagnosis. Studies have found that different individuals code and interpret medical
conditions differently.61 It is important to work with clinicians to understand how we can
better interpret clinical notes to further validate diseases, especially ones that do not have
a specific ICD code. This will become more critical as genetic data becomes more
prominent in medical practice, a shift that many physicians feel ill-equipped to handle.117
Rare diseases do not provide a compelling case of the ability of our current infrastructure
to track and disseminate this information to a broad clinical base.
Data quality will increase if there is greater collaboration between clinicians and
those working to provide these estimates; researchers, registries, and organizations.46
Maintaining high-quality biologic samples and biobanks with appropriate informed
consent from patients can provide a base of samples for future investment and validation.
Centralized infrastructure for labs could provide greater consistency with the
identification and diagnosis of rare conditions.46 Establishing rare disease centers of
excellence, such as through expanding the Rare Disease Clinical Research Network42
would provide more opportunities to collect prevalence data and increase our ability to
track natural history data.
The U.S. should continue to collaborate with international efforts to address rare
diseases as a global public health challenge. The importance of including the patient
voice in drug development and state-based coalitions is well established.106 To identify
the appropriate next steps and ensure that rare diseases are being addressed holistically
within our healthcare system, a national rare disease plan should be created. There has
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been successful patient advocacy representation in the efforts to advance the science
behind rare diseases, but national plans can address aspects of care including
coordination of care, patient engagement, and early access drug programs.75 A national
plan would help identify and create a roadmap to prioritize investments that would
benefit the rare disease community, such as adopting the finalized ICD-11 codes.
Despite a number of systems to identify high-quality medical or health
information,118 many sites do not follow core standards for high-quality health
information. Even trusted sources such as government websites should commit to data
quality standards to ensure consumers can identify the source of information. Rare
disease studies may be limited in scope and it is important for individuals to evaluate the
quality of the information source. Identifying the source of previous estimates may help
establish new networks for collaboration. Patient advocates or emerging researchers may
want to contact the authors of previous studies to establish partnerships at clinical sites or
to establish data sharing agreements with registries.
Any new policies around infrastructure and tracking must also consider the ethical
components of patient identification. HIPPA protections limit the ability to share data
across platforms or with unauthorized entities. Although it is critical to avoid duplication
of data for diseases that may have multiple registries, these needs must still protect
patients and gather consent. Despite current protections for individuals with preexisting
conditions under the Patient Protection and Affordable Care Act’s (ACA),119 there is
political pressure to dismantle this law. It would be naïve to ignore these concerns
without ensuring the societal interest in patient identification is not at the expense of
individual harm.
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Conclusion
Current infrastructure to provide prevalence estimates would require collaboration
with medical centers, organizations, registries, and researchers conducting insurance
claims studies using ICD-10 codes. For the majority of rare diseases, this would require
establishing a clearer disease definition and validating the name of the disease across data
sites. Data quality for existing rare diseases is often inadequate according to key data
quality metrics. Rare cancers are not more likely to have better quality data or
infrastructure compared to other rare diseases. Diseases with an orphan drug have more
sources of disease information, but this may not result in higher quality prevalence
estimates overall. Diseases with an orphan drug do have more available infrastructure,
but the direction of this relationship between information and pharmaceutical investment
cannot be determined. Establishing data infrastructure and investing in the verification of
prevalence data is important for clinicians, patients, and researchers. The U.S. should
continue to collaborate internationally on initiatives to support rare disease research and
find ways to invest in systems and policies that will support better data quality.
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CHAPTER 3
THE HEALTH INSURANCE EXPERIENCE AS DESCRIBED
BY RARE DISEASE CAREGIVERS
Background
Rare diseases are defined in the United States as conditions with less than 200,000
cases.1,2 The National Institutes of Health currently lists over 6,500 identified rare
diseases. A commonly cited estimate indicates between 25 to 30 million Americans are
living with a rare disease.3 Rare disease patients experience barriers to optimal health
outcomes due to an inability to receive a timely diagnosis, insufficient treatments, lack of
knowledge among some healthcare providers, and limited knowledge or research about
the condition.4–10 Patients and their caregivers often feel isolated and helpless.8,11 In one
study, parents expressed concerns about the ability to access needed genetic
information,12 which is often key for a diagnosis.
Although not all rare diseases are chronic, the literature around the chronic
disease community can provide insight for the rare disease experience, which is often
similar. Care coordination is critical for individuals with chronic care needs and parents
often must take responsibility for coordinating the care team and being the expert in their
child’s care.6,7,13 Care access points for medical equipment and therapy are often unclear,
especially when services are provided at a community level.14 A tool was created as the
result of a qualitative study6 and online survey7 to measure the supportive care needs of
rare disease caregivers. The tool was developed to be used in both a clinical setting and in
the development of policies and programs to support caregivers. The key domains of
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necessary support included understanding the disease, working with health professionals,
emotional issues, and financial needs.15 In the development of this tool and in other
broader studies on rare disease experiences, caregivers expressed fear around the
uncertainty of the health of their family member, their financial ability to respond to
health needs, and future life decisions.6–8
Achieving positive health outcomes is dependent on healthcare access.16,17 Access
depends on a variety of well-established factors including geographic, demographic,
structural, and financial.17,18 Health insurance is a critical factor for needed healthcare
utilization, but in the U.S. insurance access and quality are highly variable.19,20 In 2016,
49% of the U.S. population received coverage through employer sponsored insurance,
35% were on public insurance, 7% through non-group insurance, and 9% were
uninsured.21 According to the National Health Interview Survey working-age individuals
with disabilities are more likely have coverage through Medicaid, Medicare, or military
benefits and less likely to be uninsured than nondisabled individuals.22 Supplemental
programs such as early intervention (EI), which provides services for children at risk for
development delays are often critical for accessing needed services, such as therapy.23
However, changes in eligibility status for Medicaid and EI have resulted in geographic
variations of care and quality outcomes.20 Individuals residing in Medicaid expansion
states were more likely to have coverage.24
Respondents to the Health Reform Monitoring Survey, a nationally representative
sample of U.S. adults, found that even with health insurance, 17.9% of families and
23.3% of individuals reported having problems paying for medical bills in 2016.25 In a
recent Gallup poll, 77% of respondents reported they are concerned or extremely
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concerned about healthcare costs and an estimated 15 million individuals deferred or
skipped recommended medicines due to costs.26
Maintaining consistent health insurance coverage is a high priority for individuals
with high healthcare costs. One study of the commercial health insurance marketplace
found that families that include an individual living with a rare disease have longer
retention with their health insurance plan (p<.0001) than families without at least one rare
disease child.27 In the 10-year study period, people on plans where the employers’ bear
the burden for enrollee’s health claims had an average enrollment for 84 months for rare
diseases families and 72.6 months for all other families. This is consistent with other
studies that found that rare disease caregivers are more likely to consider health insurance
needs when making employment decisions.6,12
Individuals with complex health conditions, such as rare diseases, often require
more health care services. It is estimated that 10% of patients account for 65% of all U.S.
health care expenditures and 1% accounted for 21.5% of all health care expenditures.28
Attempts to limit healthcare costs have included initiatives to change behaviors or shift
costs at the individual and systems level, including through managed care plans,
investment in wellness programs, cost sharing, and the reduction of benefits.29–31 In a
study of parents with children with genetic conditions, 68% expressed concern about the
financial strain associated with getting health care and covering daily care expenses for
their child.12
Roughly 300 rare diseases have a Food and Drug Administration (FDA) approved
orphan drug.32 There has been much criticism of the financial incentives and price of
orphan drugs.33–36 A study of orphan drugs on the Health Insurance Exchange Plans,

71

which were established by the Patient Protection and Affordable Care Act (ACA), found
that coverage varied within and across states from 2-82% depending on the drug.37 Many
of the drugs included cost sharing or utilization management provisions, including up to
50% coinsurance until patients met the out-of-pocket maximums for the plan.37 There is a
complicated balance between decreasing healthcare costs and meeting patient needs. To
date, there have been no published studies that describe the rare disease health insurance
experience in the U.S. through the perspective of the caregiver. The aim of the study was
to qualitatively describe the rare disease caregivers’ experience with health insurance for
their child living with a rare disease.
Methods
Study Design
In-depth interviews were conducted with caregivers of individuals living with rare
diseases. A qualitative study approach was identified to allow the subjects to guide the
development of the themes and variables of influence to formulate an understanding of
this experience.38 Grounded theory principles were used to conceptualize the study design
and analysis.39 Two different conceptual categories were identified, a disease that has an
FDA approved orphan drug and a disease without an orphan drug, to explore the
properties that shape the patient and caregiver experience.
Sampling and Recruitment
Two diseases were chosen for inclusion in the study: metachromatic
leukodystrophy (MLD) and spinal muscular atrophy (SMA). The heterogeneity of rare
diseases makes it difficult to identify a “typical” disease. MLD and SMA were identified
for inclusion in the study with the assistance of a rare disease genetic counselor. Both
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diseases have an identified genetic mutation, have varying degrees of severity within the
disease, and the age of onset can vary based on the form of the disease.40,41 It is estimated
that SMA affects 1 per 8,000 to 10,000 people worldwide.40 MLD is estimated to affect 1
in 40,000 to 160,000 people worldwide.41 Both diseases have a patient organization that
could assist with study recruitment.
SMA and MLD both impact motor function. SMA is caused by the loss of motor
neurons that impact muscle movement, especially proximal muscles.40,42 Some forms of
the disease also impact the ability to breathe and eat. Diagnosis is confirmed through
genetic testing and SMA is one of the core conditions on the recommended uniform
newborn screening panels.43 In 2016, nusinersen was approved by the FDA to treat
SMA.44 Clinical trial results found that the nusinersen group had a higher percentage of a
motor-milestone response (37 of 73 participants), compared to the control group (0 of
37). The nusinersen group also had a higher likelihood of overall survival (hazard ratio
for death, .37; P=.004).45 Other disease management focuses on symptoms or
management of specific health issues.46
MLD leads to the destruction of white matter in the brain which causes
progressive deterioration of motor skills and intellectual functions.41,47 Additional
symptoms can include loss of feeling in extremities, paralysis, blindness, hearing loss,
seizures, and the inability to speak; over time an individual loses awareness of their
surroundings. Diagnosis is made through a medical evaluation and lab tests. A newborn
screening pilot study is currently underway in Washington State.48 Stem cell
transplantation may be appropriate for some patients and other treatments focus on
symptom management or supportive treatments.47
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Individuals were eligible to participate in this study if they were at least 18 years
of age, a legal resident of the U.S., and the medical or legal guardian of a living
individual diagnosed with SMA or MLD. Recruitment messages were provided to patient
organizations that represent one of the diseases and sent through their email and
Facebook pages in September 2018-January 2019. Messages reached roughly 7,200 SMA
and 600 MLD families. Snowball sampling techniques were used to recruit additional
MLD participants. Interested participants were sent to a study recruitment screening
questionnaire to establish their eligibility and provide contact information. Individuals
provided initial informed consent and then the primary researcher contacted individuals
through email to set-up a time for the interview. Additional informed consent was
provided verbally prior to beginning the call.
Ethical human subjects approval was obtained from the University of
Massachusetts Amherst Institutional Review Board. All participants received an informed
consent information sheet and provided verbal informed consent prior to the start of the
phone interviews. Data collection methods and research procedures were clearly
documented and findings were considered to be an accurate and truthful reflection of the
experiences of parents with a child with a rare disease.
Data Collection
Thirty-two individuals completed the screening questionnaire and 15 completed
an interview. The other individuals did not respond to the emails to set-up a time to
complete the interview or became unresponsive while trying to set-up a call. Calls were
made to an individual’s phone using Skype, a conferencing software, as in-person
interviews were not feasible due to travel and time restraints. Interviews were conducted
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by the primary researcher who has extensive professional experience with the rare disease
community. Calls lasted an average of 29 minutes. An interview script (Appendix G) was
developed prior to the interviews based on the key areas of interest for the study and the
prior literature. As the interviews progressed, relevant follow-up and probing questions
were used to gain additional insight. Interviews were then transcribed by a professional
transcription service. Transcripts were read and compared to the original recordings by
the primary researcher to ensure accuracy. Recruitment ended when the researcher
believed data saturation had been reached; no new themes were emerging from the data
and no new codes were needed for additional interviews.49
Data Analysis
Interview transcripts were analyzed using NVivo 12 software using both open and
axial coding.50 Broad a priori codes such as “cost sharing” and “navigation” based on the
categories of questions were created prior to the interviews. Coding was completed by the
primary investigator in sections, refined, and organized into thematic categories. A
codebook was created and discussed with a research assistant hired to work on the
project. The research assistant independently coded one of the transcripts and then sideby-side comparison was performed and there was discussion for any differences in the
codes. This process was completed for a 2nd transcription and only minor differences
arose, about 15% difference. The research assistant completed two final transcriptions
and the side-by-side comparison showed near identical coding, roughly 5%, the
differences were based on the inclusion of a few contextual words or phrases before or
after the statements of interest. The researcher also utilized peer debriefing to discuss the
codes with another researcher prior to constructing the proposed model.
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Results
Participant Characteristics
A total of 15 parents (14 mothers and 1 father) participated in the study. Four
parents had children with MLD and 11 parents had at least one child living with SMA.
The median age of participants was 37. The median age of their children was 6 (birth
years 1997 to 2017). Six of the participants were diagnosed the same year they were
born, the longest time to diagnosis was 4 years. Individuals lived in the South (6), North
(3), Mid-West (5), and West (1). For patient privacy, only the child’s initials are reported
and quotes include the state of residence and child’s diagnosis.
Every child had healthcare through at least one parent’s employer, eight
participants were the primary policy holders. Eight patients were also double or triplecovered through a public insurance program such as Medicaid (6) or the Children’s
Health Insurance Plan (2). Two were on a Medical Assistance Program through their state
or county, three were currently receiving additional services through their Early
Intervention Programs, and four had participated in EI until their child aged out. One
child was on Medicare. Most individuals did not differentiate between their public and
private insurance experience and some commented that they were not aware of the
specifics between the plans or what was covered under what plan mechanism.
Model
The Rare Disease Caregiver Health Insurance Experience Model (Figure 3) was
created by the principle investigator to contextualize the experience as described by rare
disease caregivers. The model was then shared and furthered refined through
collaboration with other members of the research team. Critical individual factors
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include demographics, location, employment, and the patient diagnosis. Emotional
factors such as uncertainty, urgency, and responsibility also impacted decisions and
involvement. Health literacy was a product of individual factors and evolves over time
as an individual navigates the system and identifies strategies to successfully engage
insurance companies. Established external factors of accessibility, availability,
acceptability, and healthcare quality impacts an individual’s opportunity to obtain
insurance. Politics was added to reflect the importance caregivers placed on the impact of
political decisions, such as protections for preexisting conditions. An individual’s
potential involvement in the insurance process was signified by the lines with a heavy
border. Emotional and knowledge support was provided by external forces throughout
the process.
Obtaining, interacting, and accessing coverage decisions are where individuals
encounter obstacles. Obtaining insurance can be complicated by the options available
and whether an individual qualifies. Interacting with the insurance company requires
complex documentation, redundancy in reauthorizations, time, and can result in
incomplete information or being bounced to multiple sources in the company. Accessing
can result in approval of claims, coverage questions between multiple insurers, and costs
to the patient. Individuals may dispute these claims, requiring further interaction.
Coverage decisions may require the individual to access outside financial assistance. The
result of this access can impact the health outcomes for the child, either improvements
or medical setbacks, which can change the way an individual interacts with the system.
The results of this process and the child’s health impacts overall satisfaction.
Figure 3: Rare disease caregiver health insurance experience model
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Health Literacy
Individuals showed high health literacy by identifying clear strategies related to
how they navigate healthcare. Some people had confusion around the health insurance
documentation, such as the benefit descriptions and explanation of claims. Most had
identified strategies to get the information they needed, but most still found it challenging
to navigate on their own, even if they were part of the health system.
I mean, I am far more comfortable than the average person. I’m a physician myself.
Although, I have still found it to be overly complicated and difficult, despite the
years of, you know, training in the system. (SMA, TN)
There was a strong sense that navigating insurance correctly was a necessity. Some
people wanted more help in finding information, while others did not believe clearer
answers existed or that insurance was willing to provide them. Individuals spoke about
the iterative process of learning the system and piecing together information over time.
You know, we have talked to a lot of organizations and individuals over the course
of her 11 months of life, but I think it has really fallen to us to educate ourselves.
So, I mean, we’ve probably talked to 50+ people from advocacy groups, to
disability coalition, to lawyers, to case workers, to social workers to, you know,
political advocates, and I think each person has provided us with a little piece of
information, but it’s kind of remained up to us to sort of figure out overall how to
navigate the system. (SMA, TN)
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Involvement and Support
Parents felt obligated to research their needs, chase down answers, and secure the
authorizations directly from the insurance plan. People described keeping detailed notes
of everything they were told by insurance agents. Often, they were reliant on medical
professionals or other advocates to write letters for medical necessity or to get them
started in the right direction for securing approvals of healthcare services. Sometimes this
help came from within the community of families living with the disease, such as an
SMA specific health insurance Facebook page. In some cases individuals would
passively wait for claims to move through the system and “resolve themselves”, but most
individuals indicated they needed to be vocal and involved for success.
Yeah, so I kind of go into mama bear advocate mode. [laughter] And I don’t like
going to that place, because it usually means I have to be very assertive. I always
try to be super polite, so I hate having to be aggressive with them. But it usually
means I have to do a lot of follow-up calls or I have to do a lot of follow-up
paperwork. (SMA, CA)
Many individuals tried to pre-plan their short and long-term care health needs and
work with insurance to see what might be covered in a specified timeframe. The purpose
was to get needs met quickly and anticipate potential denials or reauthorization periods to
limit disruptions in care. Caseworkers within the insurance company were sometimes
provided proactively, while other individuals requested one. Caseworker quality was
described as highly variable but improved if the caseworker stayed with the family over
time. Individuals felt that caseworkers had the potential to help navigate the terminology,
documentation, or indicate areas for saving money. Some individuals felt this was
successful to help them plan, but many others felt that insurance would not provide clear
answers or the answers they were given changed.
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So, and we did have a case manager with my husband’s insurance, I don’t know if
we triggered some sort of, you know, like, high cost flag or something.
[laughter]… And I never found that person terrible useful. You know, like, I had
these conversations and I explained our situation, and she just really couldn’t
provide me assistance in any sort of useful way. So, I liked the idea, but it didn’t
turn out to be what I hoped. (SMA, IL)
You know, it’s not something you’d notice the next day, like, some service kind of
message or something like that, it’s just we would be missing out, and we
wouldn’t know what we’re missing out on or what’s available down the line.
(SMA, NY)
Emotional, logistical, and knowledge-based support was proactively sought by
parents or provided at many points in the process of navigating insurance. Disease
specific organizations, disability organizations, or social services agencies were often
seen as a valuable starting point for support and knowledge. Providers were also seen as
supportive knowledgeable resources. Conversely, providers could be a barrier if they did
not believe that a test or treatment was necessary. Benefits managers or members of the
leadership team, such as Presidents, at the place of employment provided guidance and
intervened to get benefits on behalf of some of the families. Most individuals spoke
about the importance of peer support to find others who understood their experience and
could provide valuable insight on navigating insurance. Often this came from connections
made through organizations or social media, especially Facebook.
There was at least one time I remember specifically, where I was receiving
incorrect information from our insurance company. I went online. I was put on
hold, because they were trying to figure things out, and I went online, and I said,
“Hey, who here has this insurance company and was told that?” And literally 30
seconds later, another mom wrote in to say, “We do. This is what I was told, and
this is what you need to tell them.” So by the time I got off hold, they were like,
“Here.” I told them, “Here, this is what it is. No.” I was like telling the insurance
company, “This is why. It really is.” (SMA, TX)
Obtaining Insurance
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All individuals stated their child had consistent insurance coverage. Some
participants had difficulty obtaining secondary insurance or described the process as
daunting and time consuming. Individuals described both positive and negative aspects of
state specific eligibility criteria or benefits. Secondary insurance, such as Medicaid, was
seen as critical to unlocking access to some forms of care, including nursing services and
therapy. Only MLD caregivers discussed their lack of a diagnosis as a barrier to being
able to qualify for secondary medical insurance, but individuals from both disease groups
discussed challenges.
Almost every single state in this country has a waiver that allowed medically
disabled children to get on the state Medicaid system, so that they can get access
to all of those services, regardless of parental income, and our state does not have
that, so that has been incredibly difficult for us, and has been a major barrier in
getting her care, you know, nursing, and some of the equipment that is only
covered by Medicaid, it’s not covered by private insurance. (SMA, TN)
Employment was a major factor in obtaining insurance and many people felt
limited in their coverage based on the options available to them through their employer.
The scope of benefits was also attributed to the size of the employer, especially in
covering unique services or treatments.
That might work for, like, a Walmart, where it’s spread over 50,000 employees,
but the [organization] that I work at has 300 employees, so if you added a rider
saying, “Nursing for SMA is now covered,” and everyone’s premiums go up $5,
they all know I am the one using that. (SMA, NY)
Their child’s health insurance needs were cited as a determining factor when
considering employment decisions and contributed to job loss fears. One individual spoke
about fears of repercussions for being “too costly”, despite the legal ramifications of
discrimination.
Insurance will always be a determining factor of taking on a new job, because if
their insurance doesn’t cover what this insurance does, then, you know. (SMA,
MD)
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Interacting
The time needed to interact with insurance and processing claims was one of the
most prominent obstacles. One source of delays in approvals or claims was related to the
interplay between multiple insurers or providers incorrectly submitting claims to the
wrong insurer. Getting through the automated systems and first tier customer service
representatives to get accurate information was especially complicated with the realities
of life.
And so, especially if you’re trying to manage – you have other children and you
work and you’re trying to keep a household and what not, it’s hard to sit on the
phone for 30 minutes waiting for someone to help you, and then, you may get
redirected five times. (SMA, CA)
Many of the SMA parents discussed the wait time associated with the FDA’s
approval of nusinersen and the additional time to get access to the drug through
insurance. The sense of urgency for the health benefits of nusinersen were palpable, one
individual even structured her birthing plan around getting her child a Social Security
number, which is necessary for health insurance enrollment paperwork, to access the
nusinersen as soon as possible. Individuals in this study whose children received
nusinersen within a few days of being born, stated their children were essentially
asymptomatic and did not require any specialized care beyond nusinersen.
A lot of it came down to the cost because it’s so costly per injection. U of M
wasn’t just going to give her the treatment and figure out the billing later and
insurance was going to take their sweet time looking at it, so like we're just kind
of stuck somewhere in the middle. And 30 days is a long time when your child is
waiting for a life-saving medication. (SMA, MI)
Some people believed that they could interpret their benefits themselves, but most
felt they needed help to decode the information. When individuals tried to contact the
insurance company, they often had to talk to multiple people before finding someone who
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could provide an answer and many cited times when they felt that they received different
answers from different people. The lack of transparency in tracking claims and the
inconsistency in approvals was a large obstacle. Correctly submitting documentation was
described as a team effort. Providers submitting claims to the wrong insurer or incorrectly
submitting claims using the wrong code could result in claims sitting in limbo for months
or denials. Certain treatments, referrals, and equipment required reauthorizations, the
repetition to continually prove the same medical necessity or on-going care needs was
seen as time-consuming and as a disruption in successful care routines.
At least the specialists that she will need for the rest of her life, it would be very
nice if we didn't have to get referrals all the time and then sort of deal with, “Oh,
you know, this appointment wasn't covered under the years’ worth of referrals
that we sent in that time.” (MLD, NY)
For example with M’s Synagis injection last year, we waited like 2 months for
insurance to approve it, and I got a letter like two days after Christmas they
approved it, and then the new year started so we had to get a new approval… She
doesn't have something that's just going to get better or go away. She’s always
going to have it; so I just don't know why we have to keep running through the
same circles for the same thing. (SMA, MI)
The insurance companies’ comprehension and understanding of the medical
situation seemed inadequate to most participants. This was related to both a
misunderstanding of the medical needs and the complete picture of other care needs, such
as equipment or services to help with day-to-day living. Due to the lack of knowledge of
the disease, parents wanted insurance to try to understand their case history or defer to the
medical professionals related to their care needs when making coverage decisions.
So, for example, she has to be on continuous pulse oximetry monitoring, which we
were denied multiple times, getting that piece of equipment, until our doctor wrote
for oxygen, and she doesn’t actually need oxygen. In fact, that’s kind of
contraindicated actually in SMA, because the problem is not oxygen delivery, it’s
muscle weakness. But the insurance company would not allow us to have a pulse
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oximeter to monitor her oxygen level, you know, in her blood, and her adequacy
of ventilation until she was written for oxygen (SMA, TN)
For her, you might need a drug that is proven for cystic fibrosis, but we know for
a fact that she has some of the same lung issues, but we may not be able to get the
insurance to cover that equipment or that drug because we don't have the
background that says, "Oh yeah, they will work for MLD too." (MLD, MN)
People wanted to be treated with a sense of respect and felt that they were being
treated as if they were trying to “game” the system, when individuals just wanted to
provide appropriate care for their child. When they did not feel heard, respected, or if
there were inconsistencies in what they were told, it often eroded trust and further
establish a need for the parents to be vigilant and fight. Many people used what they
learned as part of the run-around to devise strategies to get faster or more accurate
answers in the future.
The left hand doesn’t know what the right hand is doing, and that makes it really
tricky to navigate, because, you know, it puts more pressure on the parents or the
caregiver to do their due diligence, where I feel like it shouldn’t necessarily be all
on us to do it. (SMA, TX)
Accessing
Individuals experienced the greatest barriers to coverage for equipment, nursing
care, therapy, and out-of-network providers. Individuals who were aware of tieredfinancing schemes indicated their providers were always on the highest tier where they
would need to pay the most out-of-pocket. Seeking out of network care was discouraged
by insurance, but many caregivers expressed the frustration of not being able to see outof-network disease specialists or go to the specialty centers where children could benefit
from targeted knowledgeable care.
We live on Long Island in New York, and he wanted – it was recommended that
we go to Columbia Children’s Hospital, where they have an SMA clinic, but
originally, we were denied coverage there because it was out of network, and
basically I said, “Why?” They said I have a pulmonologist center up closer to
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home… they weren’t going to cover us going to Columbia, where we would argue
that there’s not any other SMA specialists out here. (SMA, NY)
Nursing care was a critical support for families. Finding the mechanism to get
nursing care was often described as a time-consuming challenge, especially if people
could not qualify for Medicaid. Nursing companies were often critical in helping
caregivers navigate the coverage. A good nurse was described as being invaluable to a
family and often went above and beyond in providing guidance and support, but there
was high turnover.
We only had one hour of a consultation nurse. That nurse stayed for three hours,
stayed two hours on her own time, because she felt that we were in kind of a dire
situation and didn’t have any of the home care set up, because we, you know,
didn’t know how to set up our home. Nobody took us—nobody met us at home. So
he went home without insurance covering private-duty nursing, and we had no
nursing coverage, and we were expected to stay awake all night while my son
returned from the hospital, and that did not end well. (SMA, MD)
Therapy was described as expensive and critical to helping the child achieve the
best mobility and health outcomes. Many companies had caps on what is covered by
insurance, but the terms of coverage were often unclear. Multiple people spoke about
trying to get clarity on the number of allotted hours only to be quoted wrong information
and losing access mid-year.
If you’re making, like, huge gains, which is good, but it, would be, something,
like, $28,000, which I couldn't afford. Because, it says here, physical, speech,
occupational therapy, “Subject to specialist’s office, visit copay,” which is $0,
“And 90 visits per calendar year.” So, for me, I should be able to go to wherever
we want for 90 visits a year, but I don’t really know where I can go, and for what.
(SMA, NY)
Every year, we run out of PT hours, and we run out in October, so we have a hard
limit on our insurance, and every year, a nurse case manager that’s on our case
tells us, “Oh, if you get a doctor’s prescription, you can increase it.” We say
every year, “No, we can’t,” and then we spend another 90 minutes on the phone
between our physical therapy gym and the insurance company. (SMA, MD)
The out-of-pocket costs were described by some as reasonable when considering
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the scope and total cost of their care needs. There was a split between individuals who
just referred to “bills” and those who can recite their entire paradigm of premiums,
deductibles, copays, and coinsurance. Some of these fees were covered as a perk of
employment or through secondary insurance programs. Some individuals had out-ofpocket maximums for the year. Those who had deductibles spoke about how quickly they
met them.
And then we have like a per-person ones, like M's is 500 and she meets that within
like 30 seconds in the new year so. (SMA, CA)
The cost of equipment, drugs, therapy, and out-of-network services were
described as the most expensive parts of care. These types of services often had costsharing mechanisms, but the patient’s portion was still quite large.
So, you know, 20% – or, I guess it’s 10% drug. But anyway, you know, a 10%
copay on a $150,000 per year bill is, like, prohibitive for most people. (SMA, TN)
Different values contributed to different expectations about what should and
should not be covered, especially around equipment and quality of life supportive
technologies, such as powerchairs and adaptive beds. Some individuals were narrowly
focused on specific medical costs, while others looked at the full paradigm of care and
support. Many expressed that if a doctor indicated that something was medically
necessary, families should have an affordable way to access it.
Again, I know there are like private groups that you can go on funding and you
can do social funding, but things that like are clearly medical necessities in order
to be able to navigate the home and reach the home and go to the doctor's
appointments, for example, seem like they should have better coverage. (MLD,
MA)
Insurance was described as one piece in the larger financial structure, but timely
complete information was necessary for long-term planning. Almost all of the SMA
individuals received nusinersen with assistance from the clinical trial or the drug
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company’s copay assistance program. Early intervention was described as a key safety
net program for individuals to get started, but there was concern about what would
happen when the child aged out after 3 and this assistance ended. The expectation is that
schools will provide services and equipment. The variability of school resources,
knowledge, and capacity to support students was identified by the parents. An individual
often needed to decide when to utilize outside sources of assistance, such as grants or
fundraisers.
And I really think that when you look at someone's care needs you know
insurance is one part of it but it's really like trying to understand all of the
benefits including insurance that they are entitled to and how all of those pieces
need to work together. (SMA. MN)
A few individuals spoke about how they have not accessed any other sources of
financial assistance due to time, a sense of greater future need, eligibility, or they felt that
others required the assistance more. Many people reflected on how they did their best to
contribute their fair share and to cut costs by repurposing supplies or using equipment
shares, but they wanted insurance to understand the importance of the needs they did
submit.
Now, I am trying to get some equipment for her mattress and I am just trying to
get it paid for with the proper paperwork signed and everything to get it through
and it is almost like I feel if I did the financial analysis on how much it costs to
take care of a wound, they would certainly rather pay for the mattress, it is 300
bucks instead of the $3000 that it is going to cost if I have to put her in the
hospital time and time again. (MLD, MN)
A few individuals spoke about shifting formularies, gatekeeping requirements,
networked providers, and benefits that sometimes changed how the individual could
access care. Sometimes these changes would be related to eligibility shifts, such as a
provider who was included in Early Intervention, but out-of-network when the child
aged-out. Other insurance changes would not be communicated to families directly and
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might only be uncovered when individuals received a bill or were outside of their plan’s
scope of coverage.
The state of Illinois doesn’t really care that she’s out of network, but then, when S
turned three, we have to deal with the insurance and her billing and stuff directly.
(SMA, IL)
Many people discussed the concern about the health consequences of the delays
or denials of the insurance company, especially the potential for worst health outcomes or
lost opportunities, such as clinical trial participation. People spoke about how the
coverage they could access would impact their life decisions, such as having more
children. Many expressed a sense that things were not fully in their control and they only
had so much bandwidth to continually fight. The political climate and fears of losing
protections for preexisting conditions weighed heavily on many. Only a few people spoke
directly about their own mental health.
Satisfaction and Health Outcomes
When asked if individuals were satisfied with their insurance, many said yes,
despite describing challenging experiences. One respondent stated, “That’s kind of a trick
question.” Those who were most satisfied had decent benefits or had overcome a large
obstacle with coverage. Some people were very distrustful, but most expressed a sense
that they wanted to work better with the companies to find the best way to balance their
child’s needs, doctor’s recommendation’s, and cost-savings.
It can be a nightmare if the right people aren’t in place to monitor it… Yeah, so
because everything is pretty covered for her, and we, again, knock on wood, are
pretty healthy, there’s not a lot of – I don’t feel that I am having to follow up with
insurance companies or, you know, ask for things to get taken care of. (MLD, TX)
It shouldn’t be about, “Oh, sorry, you can’t have this because it’s too expensive.”
Well, but that’s what the patient needs. So, if that’s what the patient needs, find a
way to make it more affordable so that they can have it. (SMA, CA)
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A few reflected on the importance of taking care of each other and how their
experience has impacted their individual value sets. Individuals also looked at their own
privilege related to education, support, and the severity of their child’s condition when
reflecting on their experience compared to others. This sometimes resulted in not
accessing certain financial resources or finding ways to give back to others in the
community in whatever way they could.
And it's like basically, I think you know could be a part-time job for someone. And
so, for people who perhaps are not native English speakers or who don't have a
level of education that allows them to sort of navigate through these systems or
don't have the time to be on the phone for you know 10 hours a week on hold or
whatever, I think really is a disservice and kind of a shame. (SMA, MN)
When looking at what changes caregivers most wanted to see, many people spoke
about making the process more user friendly, decreasing the time it took to interact and
get approval answers, and reducing the need for reauthorizations for on-going needs.
Communication was a consistent theme including a desire for a clear line of direct
communication, greater transparency, and a shift to more consumer-focused care. People
wanted to be treated humanely and with an understanding that they are just trying to take
care of their child.
It goes back to walking around with, you know, in somebody else's shoes and
trying to figure it out. It is not like we are trying to take advantage of anybody
when we have kids with rare genetic illnesses. It is very difficult. (MLD, MN)
I guess I just wish, like, the answers were easier to find, and they were more black
and white, like, as if it was more like a puzzle, and felt like, “You know, isn’t this
the point of having a job and health insurance, so that when you have something
you need, like, you’ll get it?” (SMA, VA)
I mean, I hate it, but it has to be done, because we can’t afford to not have it be
done right, so we just have to continue to keep this documentation of every call
and every time and what they said, because I feel like I’m more organized than
they are, and I feel that I have to be, because my daughter’s definitely worth it, so
this is where we have to be. (SMA, TX)
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Discussion
The purpose of including MLD and SMA was to explore the potential differences
in the presence of an orphan drug for patients accessing medical care. However, these
preliminary results indicate limited differences in the caregiver experience based on the
availability of an orphan drug. This is consistent with previous findings that rare disease
care needs are largely similar despite disease differences.6 SMA patients with early
access to nusinersen, did not experience many further healthcare coverage needs, which
was different from their peers whose children still required complex care needs. Both
SMA and MLD parents had to fight with insurers to gain access to services and products
seen as medical necessities. The MLD care needs are less established, which often
required additional justification to ensure insurance coverage.
Parents and medical professionals often were looking at long-term needs and
outcomes, while insurance was more focused on more immediate utilization controls
aimed at reducing access to expensive drugs and services. This applied to the medical
pay-off of certain equipment in preventing hospitalizations or medical complications and
the approach for finding an MLD diagnosis; test-by-test vs whole genome sequencing
which could provide a broader scope of genetic data. This is consistent with studies that
indicate that diagnosis can take years.8 The negotiation between insurance company and
patient interests will likely create inequities based on an individual’s health literacy and
overall access to knowledgeable providers. As a society, we must decide how we believe
these negotiations should go and what entities we believe should be driving decisions.
Managed care models of insurance rely on patients using in-network care.
However, rare disease diagnosis may rely on numerous visits to specialists in multiple
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locations9 and may only have a handful of experts or specialty centers, which are often
organized regionally or nationally.10 Patients may need to seek care outside of the
insurer’s negotiated networks of providers. We must find a way to balance these
competing needs to allow individuals to access disease experts, without unduly burdening
patients with greater out of pocket costs. Private insurance companies are often only
temporary stewards of an individual’s health as individuals are assumed to change plans
every few years. Long-term savings, such as through supportive technologies, may not be
as important as the year-end bottom line. However, with complex conditions small
setbacks can become incredibly costly and disruptive to the health of the child and the
life of the family.
Currently, there are assumptions related to the care paradigm that most people
will navigate, including logical places to gain access to certain services based on
demographic factors. However, if a state has exclusions to secondary insurance or if an
individual has more complex needs then can be addressed at the site (such as a school),
the system is not equipped to adjust. Complex care cases have few options for recourse
within the system and may toil in limbo or fall through the cracks, unless caregivers can
devote the time and energy to fight for needed services.
A few individuals interviewed commented on structural changes or unique
providers that were seen as beneficial. One had a complex care provider through the
hospital that was able to serve as the gatekeeper and primary navigator for other points of
care but was equipped with the specific knowledge of complex care needs and available
resources. Another individual spoke about the integrated financing and delivery system
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for the Medicaid program in their state, which from their perspective made the process
when accessing services more seamless.
Based on the interviews, policy changes or insurance company initiatives that
could improve the experience of rare disease patients include establishing time limits for
processing coverage decisions and increasing the transparency in the claims and
preauthorization process. Allowing options for universal authorizations for certain
domains of care or changing the frequency of the reauthorizations would also decrease
the burden on families and medical providers to continually prove medical necessity.
More research into the natural history of rare diseases and establishing medically
recognized treatment guidelines would improve evidence-based care for patients,
especially if insurance was required to provide coverage for the services necessary to
follow those guidelines.
Training insurance specialists that are familiar with complex and chronic care
needs, are trained to review medical records, and can interface with this population in a
respectful way, would also increase the overall experience for patients. It is unrealistic to
expect insurance companies to become experts in every rare disease, but there should be
a framework for assessing claims to make coverage decisions without unduly delaying
progress or harming patients. Individuals who felt that there was someone at their
insurance company who could intelligently answer questions, had far fewer complaints
than those who did not.
Our healthcare delivery system is moving towards centers of excellence or a
centralized hub model of for specialist care, but our payment systems often require innetwork care. In many cases, there are limited options to choose more flexible plans.
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Individuals with compelling needs to see an out-of-network specialist should have an
opportunity to seek waivers from out-of-network care cost restraints or to seek expert
opinions in a cost-effective way. This goal would be easier to achieve if health insurance
companies were incentivized to invest in an individual’s long-term health outcomes. As
the U.S. investigates single-payer healthcare options, which would likely integrate
payment and delivery networks, we need to identify appropriate ways to make allocation
decisions for the long-term health of an individual. Successful policy changes must
include the patient voice to ensure that solutions for a sustainable healthcare system are
flexible for adapting to evolving patient needs.
Limitations
The estimated MLD population is smaller, recruitment was more challenging as
the disease organization infrastructure is less developed. Every MLD caregiver who
participated offered to help recruit. This likely means that the MLD participants joined
due to personal outreach and snowball sampling, where most of the SMA participants
self-selected due to general recruitment messages. The SMA group also did not include
any individuals who are not currently using nusinersen, the overall proportion of
individuals on the drug cannot be determined, which makes it difficult to assess the
impact of this representation. There is a limit on the amount of time caregivers can give
and it is possible that we are missing the perspective of individuals who are in even more
dire financial situations. Insurance status was self-reported and cannot be validated, but is
likely accurate due to the level of involvement most caregivers had in their child’s
insurance.
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Although, there was some geographic diversity, some states included multiple
participants including Minnesota and New York. The study also put a large importance
on equipment and therapy as these are key features in diseases with mobility issues, other
rare diseases are likely to have slightly different needs, which may result in other
unexplored challenges. However, we believe that the themes and the model provide a
medically agnostic starting point to the overall caregiver experience. Finally, as a
qualitative study the results could be subject to other interpretations, but this was limited
due to the use of double-coding and peer-debriefing.
Conclusion
This study adds to the scholarly research and literature and has the potential to
improve practice and policy. There are possible policy initiatives that could impact our
payment and delivery systems that could greatly improve patient experience and
outcomes. However, it is critical that the patient voice is represented in efforts to
establish a framework for assessing and approving care needs. Parents with a child living
with a rare disease are required to meticulously track insurance in order to maximize
benefits. They are often asked to navigate difficult decisions to balance medical needs
and financial stability. Individuals are often grateful for a supportive network of peers
and providers, but the final responsibility falls to them.
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CHAPTER 4
MEDICARE PART D ORPHAN DRUG EXPENDITURES
FROM 2013 TO 2017
Background
Rare diseases
In the United States, a rare disease is a condition that impacts less than 200,000
people.1,2 An estimated 30 million Americans are impacted by one or more of the roughly
6,500 identified rare diseases.3 The diseases are clinically heterogenous and an estimated
60% are genetic in origin. Many of the conditions have insufficient research resulting in
undefined clinical guidelines, limited treatment options, and inadequate knowledge
among some healthcare providers.4–10 Individuals living with rare diseases often feel
isolated and can face challenges finding an accurate diagnosis and treatment plan.8,11
Orphan drug coverage and expenditures
Orphan drugs are products designated for the treatment of rare diseases. The 1983
Orphan Drug Act (ODA) provides economic incentives for the research and development
of orphan products including 7-year marketing exclusivity, fee-waivers, and grant
opportunities.2 Companies developing a product submit an application to the Food and
Drug Administration (FDA) to establish eligibility for obtaining an orphan designation.12
Drugs are eligible if they are intended to treat a disease that affects fewer than 200,000
people in the U.S. and there is no expectation of recovering the research, development,
and marketing costs from U.S. sales of the drug. This process can occur at any point
between laboratory drug discovery and clinical trials in the drug development process.12
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Once there is evidence related to the safety and efficacy of the drug, the company
submits a marketing application to the FDA. The FDA approves the drug’s indications,
the identified uses for the drug. Indications are based on the clinical trial information and
the marketing application materials. The indication is often narrower than the orphan
designation and may only include a subtype of the disease or a specified patient
population.12 Between January 1983 and August 2018, 503 drugs were approved with an
orphan indication. Of those drugs, 394 (78%) were only approved for the orphan
indication, while 109 (22%) also had a non-orphan indication.13
There has been criticism related to the price of orphan drugs.14–18 Using 2017
invoice prices, the median annual cost for an orphan drug was $46,800 per year and the
mean was $87,319.13 Of the 374 orphan drugs that were on the market in 2017, 301
(80.4%) had an annual cost of over $6,000 and 73 (19.5%) of the drugs had an annual
cost per patient of less than $6,000.13 Of those, 109 (29.1%) were oncology products with
an annual cost of over $6,000 which represented 40.8% of all orphan sales.13 There are 5
orphan drugs (1.3%) that are priced over $500,000 per year, which contributed to 1.8% of
total orphan drug spending.13 The average sales for the 50 highest-selling orphan
products was $639.5 million and the next 50 highest selling products averaged $139.5
million in 2017.13 These costs may not reflect what an individual or a payer actually
spends based on the availability of medication assistance programs or coupon programs.
Patients are experiencing high healthcare costs, for drugs and other medical costs.
A nationally representative sample of U.S. adults found that 17.9% of families and 23.3%
of individuals reported having problems paying for medical bills in 2016.19 A Gallup poll
found that 77% of respondents reported they were concerned or extremely concerned
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about healthcare costs and an estimated 15 million individuals deferred or skipped
recommended medicines due to costs.20 Studies that focused on families living with rare
diseases or genetic conditions also report concerns related to financial stress.7,21 In
oncology, the term “financial toxicity” has been used in the healthcare literature to
describe the impact of the financial burden of treatment on a patient’s overall
wellbeing.22–25 Having insurance can help decrease costs associated with drugs, but there
is a high degree of variability in orphan drug coverage across insurance plans. Insurance
access to orphan drugs through Health Insurance Exchange plans established through the
Patient Protection and Affordable Care Act (ACA) found that insurance coverage varied
within and across states from 2-82% coverage depending on the drug.26
In the research literature, orphan drugs are sometimes considered a subsection of
specialty pharmaceuticals. Specialty pharmaceuticals tend to include biologic and
injectable agents and are often used for complex conditions, including cancer and some
conditions that are considered rare.27 However, there is not an agreed upon definition for
specialty drugs. One definition is based entirely on the cost of the drug; for 2019 one
definition is a drug that costs at least $670 per month.28 Another definition requires that a
drug meet a certain number of cost, delivery, and medical factors to be considered a
specialty drug.13,29 Specialty drugs often require prior authorization or impose quantity
limits.30 Information about specialty drugs can help inform orphan drug research.
Three studies have looked at the total orphan drug expenditures in the United
States. In 2017, total drug sales in the U.S. based on corporate sales data were $451
billion for pharmacies, clinics, hospitals, and healthcare providers; with $43 billion
(9.5%) attributed to orphan drugs and another $157 billion (34.8%) attributed to non-
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orphan specialty drugs.13 A 2017 study found that orphan drug spending was $36 billion
(7.9%) of the total $450 billion drug sales in 2016.13 The study also found that orphan
drugs contributed $14.6 billion of growth in spending from 2011 to 2016 while nonorphan specialty drugs saw $74.6 billion in growth in the same time period.13 In 2013,
orphan drug spending totaled $30 billion (8.9%) of total pharmaceutical expenditures in
the U.S.31 Oncology drugs represented $12.22 billion (40.7%) of the total orphan drug
expenditures.
Internationally, orphan drug expenditures represent less than 6% of total
pharmaceutical expenditures. In 2007, a study of 5 European countries found that the
percentage of orphan drug spending as a percentage of total drug spending was 1.7% in
France, 2.1% in Germany, 1.0% in the UK, 1.5% in Italy and 2.0% in Spain.32 More
recent studies found that the orphan drug percentage of total pharmaceutical spending
was 5.6% in Canada in 201333, 2.7% in Sweden in 2013,34 3.2% in France in 2013,34
1.9% in Belgium in 2008,35 4.2% in the Netherlands in 201236, and 3.3% in Europe in
2010.37
Medicare Part D
Medicare Part D is a prescription drug coverage plan that was implemented in
2006 and is administered by the Centers for Medicare and Medicaid Services (CMS).38
The program provides pharmaceutical coverage for individuals enrolled in Medicare.
Medicare is a health insurance program that was established in 1966 for the elderly and
was expanded to individuals with permanent disabilities in 1972. In 2018, 43 million
people were enrolled in Medicare Part D.28 The majority of individuals (58%) are
enrolled in a stand-alone prescription drug plan (PDP), while the remaining 42% are in
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Medicare Advantage prescription drug plans (MA-PD). The Low-Income Subsidy (LIS)
program provides premium and cost-sharing assistance for roughly 12 million (39%) of
Part D enrollees.28 Dual eligible individuals who receive benefits through Medicaid and
Medicare, are required to participate in Part D.
The majority of individuals enrolled in Medicare Part D are over the age of 65,
but 8.6 million people (14.4%) are under the age of 65 and qualify due to a long-term
disability.39 An individual who has received Social Security Disability Insurance benefits,
based on a long-term physical or mental impairment that will last for more than 24
months, can become eligible for Medicare. If an individual has end-stage renal disease or
amyotrophic lateral sclerosis, the individual can begin receiving benefits without the
waiting period.28 The Compassionate Allowances program identified a list of conditions
that have already been evaluated to qualify as a serious disability, many of these
conditions are rare diseases.40 The program was established to reduce the wait time for
individuals with serious conditions to receive Social Security benefits.40
Compared to beneficiaries over the age of 65, younger Medicare beneficiaries are
more likely to be male (55% versus 44%), have lower incomes, and are more likely to be
Hispanic or black.41 In 2012, 65% of younger beneficiaries had a cognitive or mental
impairment, compared to 29% of beneficiaries over 65.41 A similar proportion of
beneficiaries from both age groups reported having five or more chronic conditions, 31%
for under 65 and 28% for over 65.41 Nearly 35% of younger beneficiaries are dual
eligible for Medicare and Medicaid, compared to 10% of beneficiaries over 65. 41
Seventy-five percent of Medicare beneficiaries under the age of 65 are enrolled in a Part
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D plan and 55% qualify for the Part D LIS. Sixty-three percent of older beneficiaries are
enrolled in a Part D plan and only 16% qualify for the LIS subsidies.41
Medicare Part D has been credited with a decrease in total out-of-pocket
expenditures for beneficiaries.42–46 After Part D implementation, there was evidence of a
shift in drug expenditures from private insurance and Medicaid to the Medicare
program.43,46 Some studies also showed a decrease in hospital admissions for individuals
who were enrolled in Part D plans.47,48 Medicare beneficiaries can be subjected to high
out-of-pocket expenditures through cost-sharing mechanisms and can find it difficult to
identify the right plan for their needs.49
Part D cost sharing mechanisms
In 2019, there were 901 unique Medicare Part D prescription drug plans offered
across the country, with at least 22 plans available in each state.50 The average premium
for Medicare PDPs in 2018 was $41 per month and the average MA-PD was $34.28
Deductibles were included in 45% of plans.28 Most of the plans included a formulary that
lists the covered drugs under the plan. Formularies were required to include at least two
drugs in each prescription class or category, the included drugs can change during a plan
year.51 Cost-sharing differs across plans and drug types, with higher-cost sharing for
brand drugs and drugs that were off-formulary.30 There can be considerable variation
across plans, one study found that cost-sharing for a 30-day supply of 10 brand drugs
could be between 2 to 14 times higher on a particular PDP compared to another.30
Copayment and coinsurance rates in drug plans were established based on a tiered
system, with different costs for drugs in different tiers, with higher payments for drugs on
higher tiers.52
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Once an individual on Medicare Part D has spent a certain amount of money,
most plans require that the individual enter a coverage gap or “donut hole”.53 While in
this gap, individuals pay a larger share towards drugs until the end of the plan year or
until the catastrophic coverage amount is reached. In 2019, the coverage gap begins after
an individual and the plan spend $3,820 on covered drugs.53 While in the gap, an
individual pays 25% of the plan’s costs for brand name drugs and 37% for generic drugs.
In 2019, an individual leaves the coverage gap and operates under “catastrophic
coverage” after the person has spent $5,100 out-of-pocket.54 For the rest of the year,
drugs are subject to 5% coinsurance. The ACA legislated the closure of the coverage gap
and in 2020 an individual will be responsible for 25% of the costs for brand name or
generic drugs while in the gap.55
Part D access to drugs
A 2010 study of Medicare Part D coverage of 99 orphan drugs found that each
orphan drug was covered by 87% of MA-PDPs and 84% of PDPs.56 Four drugs were not
listed on any PDPs, but all other drugs were covered by at least 50% of national plans.56
There is higher coverage for national plans (86%) compared to plans that are only offered
in certain states (77%). Within nonnational plans, 23% of drugs have low or no
coverage.56 Of the covered drugs, 19 (20%) were covered by less than 50% of the
nonnational plans. Of the covered drugs, 84 (88%) were on tier 4 or higher on at least one
PDP and 28 (29%) were placed on tier 4 or higher by at least 75% of plans.56
Drug approval can occur through traditional channels or accelerated approval
pathways.57 A study of FDA approved therapies that used novel approval pathways
identified 144 therapeutics, of which 45 (31%) were approved with an orphan
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designation.58 Overall, 129 (90%) of the drugs in the study were covered by at least one
Medicare plan, 93 (65%) drugs were covered by at least half of the plans, and 22 (15%)
were covered by all of the plans within one year of approval.58 Three years after the
approval of the drug, 140 (97%) were covered by one plan, 112 (78%) were covered by at
least half, and 40 (28%) were covered by all of the plans. The median proportion of plans
covering the orphan drugs in the study was 62% (IQR=43-92) at one year post-approval
and 79% (IQR=66-100) at year three.58
Part D expenditures
The average per capita spending for Part D drugs for a beneficiary under the age
of 65 is $3,817 compared to $1,159 for an individual over the age of 65.41 A study
comparing the spending patterns for people who had LIS discounts and those that did not
found that individuals who received the LIS discounts had total Part D expenditures of
$1,887 compared to $1,341 for individuals that did not have LIS or another form of gap
coverage.59 Additionally, the individuals with LIS paid an average of $148 out-of-pocket
compared to $570 out-of-pocket for individuals without supplements. Of the total
expenditures, for individuals with LIS 27.6% occurred after the individual reached the
coverage gap and for individuals without supplements to help with drug costs, 16.9% of
expenditures occurred after the gap.59 Prior authorization was required for coverage on at
least one Medicare Part D PDP plan for 80 (84%) orphan drugs and 33 (35%) orphan
drugs were required to have prior authorization by at least half of the PDPs.56
No study has investigated all orphan drug expenditures in Medicare Part D, but
studies have looked at expenditures and out-of-pocket costs for categories of drugs that
include some orphan products or drugs that have similar cost attributes, such as specialty
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drugs. Multiple studies have been conducted to look at specialty drug spending trends. In
a study of specialty drug spending in 2007-2011 for a 20% random sample of all 65+
Medicare beneficiaries, specialty drugs accounted for $7.6 billion in total pharmacy
spending in 2007 and $10.2 billion in 2011.27 Per beneficiary spending increased from
$2,641 to $8,976 in the study period. This represented 6.7% of total drug spending per
beneficiary in 2007 and 9.1% of spending in 2011.27
A study of Medicare beneficiaries from 2007 to 2011 found that spending on
specialty drugs per beneficiary increased in almost all therapeutic areas and significantly
increased in oral cancer agents ($17.5 in 2007 to $40.99 in 2011) and immunomodulators
($15.6 in 2007 to $32.29 in 2011).27 In 2010, the out-of-pocket burden for specialty drugs
decreased by 26%, which the authors theorize is related to a reduction in the cost-sharing
burden while in the donut hole.27 A Congressional Budget Office (CBO) report on
specialty drug spending in Medicare Part D using beneficiary level claims data found a
31% average annual increase in aggregate specialty drug spending from $8.7 billion in
2010 to $32.8 billion in 2015.29 The top 50 selling brand-name specialty drugs in 2015
had a weighted average retail price of $4,380, with a range of $250 to $43,000.29 The
average net price for brand name specialty drugs grew at an average annual rate of 22%
from $1,310 in 2010 to $3,590 in 2015 and a net per capita spending from $330 to $830
in the same time frame.29
Two studies looked at a sample of specialty drugs to determine the expected outof-pocket costs for individuals on Medicare Part D. One looked at 12 specialty drugs in
201630 and the other looked at 30 drugs in 2019.60 In 2016, the expected out-of-pocket
costs for were at least $4,000 and up to $12,000 for one drug30 and in the 2019 study the
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range was from $2,622 to $16,551 with an average of $8,109 across specialty drugs. Both
studies found that a significant portion of spending occurred after the individual had met
the catastrophic cap. In 2016, one-third of the total out-of-pocket spending occurred after
the individual met the catastrophic cap and for 7 of the drugs, more than half occurred
after the catastrophic threshold.30 In the 2019 study, the range of out-of-pocket spending
above the catastrophic cap varied by drug from 13 to 86%. For 19 of the drugs, more than
half of spending occurred after the cap.60 For the cancer drugs included in the study,
enrollees paid at least 70% of total OOP after the cap.60
Out-of-pocket costs can vary between PDPs from 2 to 14 times higher for brand
drugs based on cost-sharing, tier placement, and the use of copays versus coinsurance.30
Specialty drugs incur the highest costs when the drug is off formulary, 50% of the 12
specialty drugs in the 2016 study were not included on all formularies.30 Two of the drugs
included in the 2019 study were not included on any of the plans. For drugs that were not
covered by some or all plans, the median annual cost when it was not included on the
formulary ranged from $26,209 to $145,769. The median out-of-pocket costs for the 12
specialty drugs that were on some but not all plans, found that the drug was at least 10
times higher than the median cost if it was covered.60
This is consistent with another study of specialty drugs for 6 uncommon cancers,
which found that 99.21% of non-LIS individuals and 99.72% of LIS individuals in the
sample reached the coverage gap and 94.4% non-LIS and 97.96% of LIS reached their
catastrophic coverage.44 In this study the annual spending on specialty cancer drugs was
$44,764 for non-LIS individuals and $44,272 for LIS individuals. Out-of-pocket
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spending was $4,870 overall and $2,689 while in the gap for non-LIS individuals and $44
overall and $41 in the gap for LIS individuals.44
Oral cancer drugs are a specific form of specialty drug that are associated with
high drug costs. One study found that the median cost for a 30-day supply of these types
of drugs was $10,060 with a range of $5,123 to $16,093 and median out-of-pocket costs
for a median duration course ranged from $6,456 to $12,160.61 With these expenses, most
beneficiaries on oral cancer drugs left the donut hole after 1.6 fills of the product.61
Chronic myeloid leukemia (CML) is a rare cancer. A study that looked at CML patients
who were taking targeted oral anticancer medication found that 81% of patients reached
the catastrophic phase of coverage within the year and a majority of patients reached this
point within the first month.62 The median costs for the first fill of the prescription was
$3.7 for individuals with heavy subsidies, $6.9 for individuals with moderate subsidies,
and $2,309.4 for individuals without subsidies.62 CML patients with subsidized Part D
plans (68%) paid less than $2 for a 30-day supply, but 40% of individuals without
subsidies paid out-of-pocket costs over $900.62 Another study looking at newly diagnosed
CML patients found that individuals who did not have LIS coverage faced mean out-ofpocket costs of $2,600 for the first 30-days of their treatment and were less likely to fill
the initial prescription.63 For those that did fill the prescription, those with LIS subsidies
initiated the prescription in 23.7 days on average and those without LIS subsidies took
50.9 days.63
To date, no studies have investigated the total Medicare Part D expenditures for
all orphan drugs. Previous studies related to Part D expenditures have focused on
specialty drugs, but the definition has been inconsistent or does not include all approved
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orphan indications. Studies on orphan drug expenditures in the United States have not
provided aggregate or beneficiary level costs for Medicare Part D.
Objectives
Medicare Part D is a critical program for drug access for both individuals over the age
of 65 and for individuals with qualifying disabilities. The primary purpose of this study is
to determine how orphan drug expenditures in Medicare Part D compare to overall
Medicare Part D drug expenditures. This research will fill the gap related to orphan drug
costs and characteristics in this program. The specific questions this paper proposes are:
1. How do orphan drug expenditures in Medicare Part D compare to overall
Medicare Part D pharmaceutical expenditures?
2. How do orphan drug expenditures for individuals over the age of 65 in Medicare
Part D compare to orphan drug expenditures for individuals under the age of 65?
3. How do orphan drug expenditures in Medicare Part D for:
A. rare cancer drugs compare to orphan drug expenditures for drugs that do
not treat a rare cancer?
B. a drug with a single orphan indication compare to expenditures for drugs
approved for multiple orphan indications?
Data and Methods
Conceptual model
Levesque, Harris, and Russell’s patient centered healthcare access model provides
a conceptual basis for this research.64 (Figure 4) The model utilizes individual and
supply-side factors to inform the dimensions of accessibility of healthcare services. The
model was chosen based on the patient centric orientation of the model for both
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systematic and individual components of access. The model is informed by a patient’s
navigation of the healthcare system. Rare disease patients often face additional challenges
while interacting with the healthcare system, but the model accounts for the key moments
and forces that impact both the process and outcomes.
Figure 4: Patient centered health care model
Model by Levesque, Harris and Russell

This paper is informed by the supply side factors that can result in the goal of
access and positive health outcomes. Medicare Part D provides a mechanism for elderly
and disabled individuals to access drugs in a cost-effective manner, which is reflected in
the approachability and affordability domains of the model. Approachability describes
the opportunity to identify, utilize, and benefit from health services.64 Programmatic
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factors such as eligibility, cost-sharing requirements, available subsidies, and drug
coverage mechanisms, such as formularies, directly impact access and cost differences
for individual patients. Health literacy can impact an individual’s ability to choose the
best plan. However, the approachability of the system is influenced by the quality and
availability of decision-making tools.
Drug prices can impact both the acceptability and availability of drugs offered
through Medicare Part D. Acceptability refers to the cultural and social forces that impact
both the individual’s ability to engage in services and the way society judges the
appropriateness of an individual seeking that type of care.64 The acceptability of using an
orphan drug is impacted by the drug approval, drug marketing processes, and provider
perceptions of new drugs. Availability through Part D is officially dependent on drug
approval, but off-label use may present inequitable variations in access for different
patients. The number of prescribers who are writing prescriptions for orphan drugs can
help inform the availability and accommodation of an individual’s ability to find a
medical professional who is knowledgeable in the condition and can provide a
prescription for an appropriate treatment. The supply-side factors in this model can help
frame the importance of the cost, prescriber, and beneficiary data as it relates to orphan
drugs. It can also inform decisions about how to ensure adequate access to treatments.
Data Source
Drug cost data was accessed from CMS Medicare Part D Prescriber Public Use
Files for the national prescription drug data from 2013-2017.65 The data is collected
through CMS’s Chronic Conditions Data Warehouse and provides drug event records
submitted through both MA-PDs and PDP plans. Data is sorted on the drug level and
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includes the number of claims, beneficiaries, prescribers, total drug costs, and specific
information for beneficiaries over the age of 65. The aggregate costs paid by beneficiaries
with and without low income subsidies was available for 2016 and 2017.
Data on orphan drug characteristics were obtained from the IQVIA Institute for
Human Data Science information was deidentified at the drug level.66 Data was from
2016 national sales data and included total aggregate sales costs. A drug was considered
an “orphan only” drug if it only had approved indicated orphan uses and a “partial
orphan” drug if it had both orphan and common indications. The data also indicated if the
drug had a single or multiple orphan indications. If the drug was a partial orphan, the
order of approval was provided. These characteristics were verified through the FDA
Orphan Drug Designations and Approvals database.67 Drug data included the costs and
approval order for all orphan only and partial orphan drugs.
Data preparation
Data is suppressed in the National drug files if the records are derived from 10 or
fewer claims. To ensure that the missing data would not significantly impact results,
totals from the national drug file spreadsheets were compared to the grand total aggregate
costs. Missing data accounted for .002% or less for cost data in each year and .014% or
less for cost data for age specific data. Any drug record with suppressed data was coded
to indicate if the suppression was due to fewer than 10 claims for beneficiaries over age
65 or under age 65. Proportional variables for the number of claims per prescribers, the
number of claims per beneficiaries, the costs per claim, and the costs per beneficiary were
created. Proportional variables were created to compare the share of claims, beneficiaries,
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and costs associated with individuals under the age of 65 compared to all claims,
beneficiaries, and costs.
Any drug that received an orphan indication from 1983 to December 2016 was
coded as “orphan only” or “partial orphan” if they had indications for rare and common
uses. A variable was created to identify orphan drugs that had an indication for a rare
cancer based on the listed indications in FDA’s database. Variables to identify if a drug
had single or multiple orphan indications and the order of the approved partial indications
(orphan first, common first, or concurrent) were also created.
A variable for approval order for partial indications was created in the sales data.
For each partial orphan drug, the orphan spending was divided by total spending to
calculate the total proportional orphan spending. Quintiles and quartiles were created
based on total spending for the drugs. The average proportional spending was calculated
for all partial orphans by quartile, by quintiles, and by approval order group.
The list of orphan drugs was then compared to the Medicare Part D drug data and
each drug was coded according to orphan only, partial orphan, or common only. None of
the orphan only drugs had claims prior to the approved marketing date. Partial orphan
drugs were only included as contributing to partial orphan spending after the earliest
orphan marketing approval date. Any previous orphan associated spending would be
considered “off-label” and beyond the scope of this study.
Data analysis
Data analysis was conducted in Stata version 13.1. Descriptive statistics were
calculated and recorded for all variables. This included frequency counts for categorical
data and the mean, standard deviation, and range for continuous variables. Variables were
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tested to see if they were normally distributed and all variables were found to be nonparametric. Variables were then compared by drug type for each year. Kruskal Wallis
tests were conducted to compare the statistical significance of the differences in values
across continuous variables by orphan drug status. Means, standard deviation, and pvalues were reported. Unless otherwise noted, results were considered statistically
significant at p=.05.
Sign tests were conducted to compare the differences between costs for
individuals under and over the age of 65. Sign tests were also conducted to investigate the
difference in costs paid by individuals with LIS and those with no subsidies. This was
chosen over the Wilcoxon signed-rank test as the alternate hypotheses provide a direction
for the differences between variables.68
In group analysis was completed for orphan drug specific variables. Kruskal
Wallis tests were conducted to determine any differences in costs by approval order, rare
cancer status, and for drugs with multiple orphan indications compared to drugs with
single indications. Chi-squared tests were completed to investigate the statistical
significance of suppression by age and drug type and age and rare cancer status.
The proportional share of orphan spending was not normally distributed. Kruskal
Wallis tests were conducted on the weighted proportional differences for the quartiles,
quintiles, and approval order groups. There was no statistical difference between groups
for quartiles (p=.8786) or quintiles (p=.3762), the estimated costs for partial orphan
spending were not calculated by these factors. There was a statistical difference (p=.020)
in the proportion of orphan spending by approval order.
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The mean proportional weight for all partial orphan drugs (0.23941) was applied
to each partial orphan drugs’ total costs to create a new variable with the estimated
orphan contribution to cost. The median proportional weight (0.08365) was also applied
to costs for partial orphans. Proportional weighting by approval order group for orphan
first (0.3808), common first (0.236), and concurrent approvals (0.2716) was also
generated. Inverse variables for the estimated common costs for each of these three
treatments were also calculated.
The three weighting applications were then used to calculate estimated means,
ranges, and the aggregate sums of the estimated orphan and common spending by year.
Pair-wise sign tests were conducted to compare the difference in estimated orphan
spending by the three weighted estimate treatments. The partial estimates of orphan and
common spending were added to the known common and orphan drug spending for each
year and estimated totals by each model were reported.
Results
There were a total of 17,022 drug records in Medicare Part D from 2013-2017.
There were 305 unique orphan drugs with claims in this time frame. On average for all
years, there were 25,283 prescribers, 423,566 claims, and 112,896 beneficiaries per drug
per year. The differences in the average number of claims, beneficiaries, and prescribers
by drug type were all statistically significant (p=.0001) for each year. (Table 9)
Table 9: Beneficiary, cost, claim, and prescriber data by year 2013-2017
Results are statistically significant at (p<.0001) by drug type for each year.
2013
Mean
(SD)

2014
Mean
(SD)

2015
Mean
(SD)

Beneficiaries

2016
Mean
(SD)

2017
Mean
(SD)

Total
Mean
(SD)

% for
<65

31.11
117

Orphan
only
Partial
orphan
Common
Claims
Orphan
only
Partial
orphan

7,565
4,357
2,975
2,476
2,433
3,825
(55,474) (22,868)
(9,338)
(7,194)
(7,406) (26,156)
27,325
28,100
24,990
40,785
22,339
28,752
(86,124) (89,722) (81,473) (192,757) (77,788) (115,014)
108,620
117,546
122,135
125,951
130,291
120,835
(491,524) (528,441) (555,641) (577,168) (600,331) (551,563)

28,603
(170,993)
113,377
(370,661)
421,549
(2,198,31
Common
3)
Costs (in millions)
Orphan
46.686
only
(159.696)
Partial
89.942
orphan
(204.844)
27.943
Common (132.028)
Prescribers
Orphan
2,949
only
(17,231)
Partial
8,807
orphan
(27,985)

Common

25,272
(67,448)

20,794
16,233
15,175
15,197
18,748
(94,254) (61,045) (58,964) (64,456) (95,328)
104,725
105,385
159,044
85,521
113,597
(341,059) (357,472) (744,976) (321,482) (456,920)
450,049
458,932
470,576
472,778
454,595
(2,318,80 (2,383,62 (2,459,11 (2,472,92 (2,367,59
8)
5)
3)
7)
2)
51.292
59.547
70.554
79.625
62.615
(172.124) (198.763) (239.534) (288.569) (220.752)
106.943
125.502
138.552
134.772
119.883
(252.081) (302.734) (360.473) (347.672) (300.640)
33.680
37.297
38.954
40.690
35.672
(159.129) (198.223) (174.973) (172.985) (168.734)
2,044
(9,654)
9,153
(28,485)

1,514
(4,446)
7,695
(22,029)

26,635
(70,105)

27,107
(71,935)

1,230
(2,582)
9,036
(32,138)
27,631.2
0
(73,744)

1,187
(2,574)
7,156
(21,030)
28,272.4
9
(75,614)

25.43
20.32
30.58
34.08
43.98
36.92

33.42
35.00
45.36
38.77
34.29
N/A

1,733
(8,739)
8,339
(26,467)
26,975
(71,802)

By drug type, total aggregate costs were $57.606 billion (8.67%) for orphan only
drugs, $44.716 billion (6.74%) for partial orphan drugs, and $561.084 billion (84.58%)
for common drugs. (Figure 5) The average total costs per year by drug type was
statistically significant (p=.0001). In each year, partial orphan drugs had higher average
costs than orphan only or common drugs. In 2017, orphan only drugs averaged $74.6
million, partial orphan drugs averaged $134.8 million, and common drugs averaged $40.7
million in mean costs.
Figure 5: Aggregate total costs in billions of dollars by drug type from 2013 to 2017
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There was a statistically significant difference in the costs per beneficiaries by
drug type in each year (p=.0001). (Figure 6) Orphan only drugs had the highest average
cost per beneficiary in each year. In the timeframe, the average cost per beneficiary for
orphan drugs increased from $49,776 in 2013 to $92,753 in 2017. In the same timeframe,
the average cost per beneficiary for common only drugs rose from $1,505 in 2013 to
$3,920 in 2017.
The lowest cost orphan only drug was $122 in 2017 for Cetylev, a drug to prevent
or lessen hepatic injury. The drug with the maximum cost per beneficiary was $1,306,221
for Strensiq a drug approved for hypophaosphatasia, a rare metabolic disease. It should
also be noted that this drug is indicated for infantile and juvenile use and does not
currently have an approved indication for adult use. There were 30 beneficiaries in 2016
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and 40 beneficiaries in 2017 who submitted claims for Strensiq. Vimizim, another single
orphan only indicated drug for mucopolysaccharidosis Type IV, a lysosomal storage
disorder, is the only other drug to have per beneficiary costs over one million dollars. The
common drug with the highest cost per beneficiary was $533,197 per beneficiary for
Chenodal in 2017, which is indicated to dissolve gallstones. This drug had only 31
beneficiaries listed and of to the total $16 million in expenditures, $13 million is
associated with beneficiaries under the age of 65. The number of beneficiaries under the
age of 65 is suppressed, but this does indicate very high costs for a small number of
beneficiaries.
Figure 6: Average costs per beneficiary by drug type from 2013 to 2017
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Orphan only drugs had the highest average costs per claim across the timeframe
and the difference by drug type was statistically significant and increased over time.
(Figure 7) In 2017, the average cost per claim was $14,500.87 for orphan only drugs and
$878 for common drugs.
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Figure 7: Average costs per claim by drug type from 2013 to 2017
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There was a statistically significant difference in the number of beneficiaries per
prescriber across drug type by year. (Figure 8) For all years combined the average
number of beneficiaries per prescribers was 1.31 for orphan only drugs, 1.72 for partial
orphan drugs, and 1.69 for common drugs. There was a statistically significant difference
in the number of claims per beneficiaries by drug type and year. (Figure 9) On average,
there were 5.29 for orphan only, 4.91 for partial orphans, and 3.49 for common only drug
claims per beneficiary.
Figure 8: Average beneficiaries per prescriber by drug type from 2013 to 2017
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Figure 9: Average claims per beneficiaries by drug type from 2013 to 2017
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There was statistically significant difference in the aggregate total costs paid by
individuals with LIS compared to individuals who do not have any subsidies (p<.0001).
(Table 9) There was also a statistically significant difference in the aggregate subsidies
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paid according to orphan drug status in both 2016 and 2017. However, we are unable to
determine the total number of claims for individuals with and without these subsidies.
Table 10: Average aggregate total cost sharing by drug type with low-income
subsidies and without subsidies
With low income subsidies (LIS)
Mean (SD) Maximum p-value
2016 by drug type
0.0001
60,981
Orphan only
(233208) 2,391,922
Partial
274,101
orphan
(1185265) 9,839,207
304,062
Common
(1272528) 19,964,674
2017 by drug type
0.0001
62,545
Orphan only
(258323) 2,833,621
Partial
176,186
orphan
(514023) 3,643,136
304,705
Non orphan
(127259) 18,169,668

Without cost sharing subsidies
Mean (SD) Maximum p-value
0.0001
2,875,377
(10977383) 124,581,608
7,584,638
(30820336) 263,742,128
4,373,747
(17202718) 264,950,880
0.0004
3,076,643
(12570954) 143,904,384
4,831,917
(10108338) 56,076,244
4,491,525
(18116438) 410,296,864

There were 449 orphan drugs in the national sales data set, 110 did not have any
sales data for 2016. Of the remaining drugs, 255 were orphan only drugs with 100%
orphan spending and 84 were partial orphan drugs. Of those, three drugs had only orphan
spending and one drug had only common spending. The total aggregate spending in the
national sales data had higher overall spending and a higher percentage of partial
spending then was seen in the Part D data.
Of the weighted models, the mean proportional weighting resulted in the highest
aggregate ($10.7 billion total) and mean costs ($28.7 million) and the median weighted
model had the lowest aggregate ($3.7 billion total) and mean costs ($10.02 million).
(Table 10) The weighted model based on approval order estimated $7.6 billion in total
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aggregate costs in the study period and $20.3 million in mean costs. These estimates were
compared to the known costs for each year. (Figure 10)
Table 11: Aggregate total and mean cost estimates for orphan associated spending
using weighted models for partial orphan spending (in millions)
Results are the estimated proportional orphan associated costs for partial orphan drug
spending based on three models for weighting. Weighting by mean used a consistent
factor of .23941. Weighting by median used a consistent factor of 0.08365. Weighting by
approval order group was applied according to approval order with 0.3808 for orphan
first, 0.236 for common first, and 0.2716 for concurrent approvals.
2013
2014
2015
2016
Aggregate total partial orphan estimated costs (in millions)
By mean
1,528.841 1,817.829 2,223.444 2,554.148
By order
1,062.946 1,270.854 1,558.896 1,813.782
By median
534.146
635.113
776.826
892.368
Mean estimated partial orphan costs (in millions)
By mean
21.533
25.603
30.047
33.171
By order
14.971
17.899
21.066
23.556
By median
7.523
8.945
10.498
11.589

2017

Total

2,581.263
1,867.375
901.841

10,705.525
7,573.854
3,740.293

32.266
23.342
11.273

28.701
20.305
10.028

Figure 10: Aggregate total costs in billions of dollars by drug type and weighted
estimates for partial orphan costs
Estimates were based on the approval order weighted costs.
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Age specific results
There was a statistically significant difference in the total costs, beneficiaries,
claims, costs per beneficiary, and costs per claim for individuals over 65 and individuals
under age 65 (p<.0001). We reject the null hypothesis that the two values are the same in
favor of the alternate hypothesis that the value is larger for the over age 65 group in all
cases except for costs per claim. For the costs per claim, we reject the null in favor of the
alternate hypothesis that costs per claim are higher for individuals under 65 compared to
costs per claim for individuals over. (Figure 11)
Figure 11: Average costs per claim by drug type and age
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Overall, 31.11% of beneficiaries under 65. Claims per beneficiaries are highest
for orphan only drugs and show more variation for orphan drugs by age. (Figure 11)
Common only drugs showed less growth over time and are more similar between the age
groups. Partial orphan drugs have the smallest proportional share of individuals under the
age of 65 (20.32%). Individuals under 65 submitted 34.08% of all claims and 43.98% of
orphan only claims. Individuals under 65 are responsible for 35% of all costs, 45.36% for
orphan only costs, 38.77% for partial orphan drugs, and 34.29% for common only drugs.
Figure 12: Average claims per beneficiary by drug type and age
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Costs per beneficiaries by age category steadily increased over time for orphan
only drugs. Costs per beneficiaries for orphan only drug spending more than doubled in
the time period ($59,548 in 2013 to $127,812 in 2017 while the costs per beneficiary for
common only drugs increased from $3,109 to $4,908 in the same timeframe. (Figure 12)
Orphan drug type was a statistically significant (p=.018) factor for the reason for
suppression. (Table 12)
Figure 13: Average costs per beneficiary by drug type and age
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Table 12: Suppression by drug type and rare cancer status
Data was suppressed if the number of claims or beneficiaries was less than 10.
65+
N (%)
Drug Type
Orphan only
Partial orphan
Common
Total
Orphan drug uses
Rare cancer
Not rare cancer
Total

101 (42.62)
25 (48.08)
1495 (52.05)
1621

<65
N (%)

p-value
0.018

136 (57.38)
27 (51.92)
1377 (47.95)
1540
<.0001

61 (62.24)
65 (34.03)
126

37 (37.76)
126 (65.97)
163

Rare cancer
Rare cancer drugs for orphan only indications in Part D cost $24.01 billion
between 2013 and 2017. This represents 3.61% of all spending in Part D and 41.68% of
orphan only drug spending. There was not a statistically significant difference in the
average total costs of rare cancer drugs compared to non-cancer orphan only drugs
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(p=.095). (Figure 14) The average total costs of rare cancer orphan drugs were higher
than their non-cancer counterparts ($97.9 million versus $70.4 million). The costs per
beneficiary were seen to be statistically significant (p=.0014). With the rare cancer drugs
costing $33,114.07 per beneficiary and non-cancer orphan drugs costing $68,151.63 per
beneficiary. The maximum cost per beneficiary for a rare cancer drug was $146,130 per
beneficiary compared to $1,306,221 for the highest cost non-cancer orphan drug per
beneficiary.
Figure 14: Average costs per beneficiary for rare cancer drugs
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The difference in the mean proportional costs for beneficiaries under the age of 65
was found to be statistically significant (p=.0001). The mean costs attributable to
beneficiaries under the age of 65 was 21.31% for all rare cancer drug spending and
53.23% for non-cancer orphan drugs. (Table 13) A total of 98 rare-cancer drugs had
suppressed records. Of those, 62% were suppressed due to data from individuals over the
age of 65. For non-rare cancer drugs there were a total of 191 records with some
suppression and individuals under the age of 65 represented 65.97% of the reason for
suppression, which was statistically significant (p<.0001).
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Table 13: Orphan drug in-group analysis for rare cancer, approval order, and
multiple indications

Orphan drug uses
Rare cancer
Not rare cancer
Approval Order
Orphan first
Common first
Concurrent
Orphan only
Common only
Number of orphan
indications
Single orphan
Multiple
orphan

Average aggregate costs
(in millions)
Mean
p(SD)
Max
value
0.0952
97.9
(311.3) 3,310.5
70.4
(211.2) 2,551.1
0.0001
78.3
(111.5)
347.9
119.1
(303.7) 2,551.1
146.0
(240.8) 1,435.4
62.6
(220.8) 3,310.5
35.7
(168.7) 7,029.3

Mean (SD)

Max

3,310.5
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%

21.31
53.23
0.0001

60,226.9
(32,477.2)
123,787.6
25,082.3
(35,137.4)
239,713.0
17,201.8
(22,735.6)
80,411.2
70,528.0
(130,562.6) 1,306,221.0
2,686.8
(12,007.1)
533,197.3

28.42
27.86
51.41
45.36
34.29
0.513

64,389.5
(12,743.7) 1,306,221.0
39,141.1
(60,135.3)
437,481.2

2,551.1

pvalue
0.0014

33,114.1
(26,160.76)
146,130.1
68,151.6
(133,446.4) 1,306,221.0

0.0001
61.7
(198.9)
125.6
(341.9)

Costs
<65

Costs per beneficiary

47.19
33.67

Drugs with multiple orphan indications
There was a statistically significant difference in the average total costs for orphan
drugs with one indication compared to drugs with multiple orphan indications (p<.0001).
(Table 13) Across all years, there was not a statistically significant difference (p=.513) in
the costs per beneficiary for orphan drugs with a single indication ($64,389.50) compared
to drugs with multiple indications ($39,141.09). The proportional share of spending for
individuals under the age of 65 was statistically significant (p=.0001) for orphan drugs
with one indication (47.19%) compared to orphan drugs with multiple indications
(33.67%).
There is a statistically significant difference in the average costs per beneficiary
based on the approval order of the drugs. Across all years, the per beneficiary costs are
highest for drugs with only an orphan drug approval ($70,528) or if the orphan approval
occurred first ($60,226). The per beneficiary costs were lowest for drugs with only
common indications ($2,686) and concurrent designations ($17,201). The highest cost
per beneficiary was $1,306,221 in 2016 for an orphan only drug. The proportional share
for individuals under the age of 65 was statistically significant (p=.0001) and highest for
concurrent designations (51.41%) and orphan only (45.36%) drugs.
Discussion
Limitations
The Medicare Part D data only includes spending through the Part D program and
is not reflective of all orphan drug spending for Medicare beneficiaries. Any spending
that is processed through other sources such as in a hospital setting would not be
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included. The purpose of this study is to determine the impact and characteristics of
orphan drug spending through Medicare Part D, therefore, this limitation is not impactful.
It is possible that suppressed records are more likely to be attributed to orphan
drug spending due to the inherently small patient population for rare diseases. This could
underestimate the impact of orphan drug spending in Part D. However, this impact should
be very minimal as the missing data for any given year is negligible and for all years
combined represents less than .18% of the total aggregate costs.
The reason for drug use was not available in the data set and it is not possible to
accurately identify orphan vs. non-orphan spending for partial orphan drugs or any offlabel drug use. As is consistent with other orphan drug studies,31 results are reported by
drug type with partial orphan spending as a separate category of drug use to accurately
report only what is known. Even if drug use cannot be determined, partial orphan drugs
with approved orphan indications still benefit from government subsidies and have
different cost patterns. Understanding market trends is still important for identifying
trends and formulating policies.
It is also possible that proportional spending for orphan and nonorphan use
changes over time based on the rate of diffusion of awareness among patients and
medical professionals for a new drug indication. Marketing dates were used to determine
when official orphan drug use began, but drug data was only available based on the year.
A partial orphan drug that received a marketing date after December 1st was considered a
common drug until the following year to limit the over estimation of orphan associated
costs. This was based on previous studies that found that there is a delay in the time it
takes for orphan drugs to be included in Medicare plans.58 It is unlikely that significant
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orphan spending would occur in the final weeks of the year directly after the marketing
date, however, this may impact the true impact of orphan drug spending in the weighted
analysis. This was not a consideration for orphan only spending as claims did not appear
in the data set prior to the approval of any of the drugs.
Estimations on the anticipated impact of partial orphan drugs was conducted
through proportional weighting based on estimates from national sales data. The
weighting may be different for the general marketplace compared to the Medicare
population. Weighting could only be calculated on group characteristics and not by a
specific drug. Additionally, weighting was only available for 2016 sales data and was
applied consistently across all years. This could inaccurately represent the true weighting
of orphan drug proportional spending in Medicare Part D in the timeframe of this study.
Estimations on the orphan versus common spending associated with partial orphan drugs
should be viewed as estimations and a starting point for future inquiry.
This paper is unable to address any claims that were denied or differences in
approval patterns for orphan and non-orphan drugs. If an individual is on multiple
medications or drugs, we cannot look at overall beneficiary spending patterns. We are
also unable to determine differences according to tiers, formulary restrictions, or MA-PD
versus PDP plans. We also do not have any context for additional reimbursement
programs or financial assistance support for the cost sharing burden on patients. Any
available information about cost sharing is at the aggregate drug level and we cannot
calculate per beneficiary cost sharing. This analysis is critical for future studies on the
overall impact of orphan drug prices for individuals and our system, but is considered out
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of scope for this analysis. This study is the first to investigate the cost and claim trends
for all orphan only or partial orphan spending in Medicare Part D.
Orphan drug spending
Supply-side factors of approachability, acceptability, availability and
accommodation, affordability, and appropriateness are all critical in patients achieving
appropriate access to needed healthcare services which result in positive health outcomes.
This project focused on the affordability aspects of access, while also providing some
evidence for the availability and accommodation of access to orphan drugs based on the
number of prescribers per beneficiary.
In previous studies orphan drug spending accounted for between 7.9-9.5% of total
pharmaceutical spending.13,33,69 We can confidently attribute 8.6% to pure orphan only
spending and an additional 6.74% to partial orphan spending. Using the estimates from
the weighted models total orphan percentage is 10.3% using the mean model, 9.83%
using approval order model, and 9.25% using the median model.
Despite the small proportion of total Part D spending, there was a clear difference
in the average costs, costs per beneficiary, and costs per claim for orphan only drugs,
partial orphan drugs, and common drugs. A previous study of orphan drug prices found
that 80.4% of orphan drugs had an average cost per patient of over $6,000, this study
found much higher per beneficiary costs.13 In 2017, the average per beneficiary cost was
$92,753 for orphan only drugs and $31,638 for partial orphan drugs.
A CBO report found that brand name specialty drug spending in 2015 was
$33,460 per beneficiary.29 In this study, 2015 per beneficiary partial orphan drug
spending was similar at $26,229, but orphan only per beneficiary spending in the same

134

year was much higher at $64,618 per beneficiary. Orphan drugs are often considered a
subset of specialty pharmaceuticals, but these differences provide a compelling need to
further investigate our payment mechanisms for covering orphan only drugs and consider
programs that specifically target the unique characteristics of rare disease patients.
The percentage of partial orphan drugs in this study was 28% which is slightly
higher than in previous studies which found between 18 and 22% of orphan drugs were
partial orphans.13,31 This difference is likely due to the fact that the general market is
more likely to include claims for pediatric or juvenile orphan drugs compared to the
Medicare population whose target population is mainly individuals over the age of 65.
Orphan only drugs in the study have a higher percentage of claims attributable to
individuals under the age of 65 compared to common or combined drugs.
Aggregate average costs per drug were highest for partial orphans compared to
orphan only or common drugs. For all years combined, the average cost of an orphan
only drug was $62.6 million, for a common drug was $35.7 million, and for a partial
orphan drug $119.8 million. These trends do not persist for per beneficiary or per claim
costs, but should be acknowledged and understood when considering policy reforms for
stimulating orphan drug development.
The number of beneficiaries per prescribers was statistically significant across
years and was lower in each year for orphan only drugs. It is often difficult for
individuals with rare diseases to find knowledgeable medical providers. This difference
could point towards the overall consolidation of rare disease experts. Future research
should investigate additional characteristics of providers to determine where individuals
are seeking treatment and to determine if needs for this population are being met.
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We only have information about the individual cost share at a total aggregate drug
level and not per beneficiary. Cost sharing was significantly higher for individuals
without cost-sharing subsidies. The orphan only drug that had the highest total costsharing amount in 2017 was Revlimid, a treatment for multiple myeloma.30 Individuals
who did not have cost sharing subsidies and received Revilimid were responsible for a
total $143.9 million. The drug had a total of 37,399 beneficiaries in 2017. By
comparison, individuals without cost sharing subsidies on the common drug Eliquis, an
anticoagulant, were responsible for a total of $410.3 million. A total of 1,064,170
beneficiaries who used the drug. In general, 30% of people with Part D have LIS.30 If we
were to use the assumption that 70% of beneficiaries did not receive any subsidies this
would mean a per beneficiary cost of $550.79 for Eliquis and $5,496.88 for Revlimid. It
is unlikely that either of these drugs would be the only prescription a beneficiary would
need in a single year.
Age specific results
In Medicare, 14.4% of beneficiaries are under the age of 65,65 but in this study
34.08% of all claims and 31.11% of beneficiaries were individuals under the age of 65.
Individuals in Medicare under the age of 65 are more likely to have multiple chronic
conditions compared to their older counterparts, which could account for this higher
percentage of overall claims.41,46 It is possible that the total number of beneficiaries is
closer to 14%, but we cannot determine if an individual beneficiary is responsible for
multiple drug claims across the data set.
Higher per beneficiary and per claim costs for beneficiaries under the age of 65
compared to over the age of 65 is consistent with previous findings.41 The difference is
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more pronounced for orphan drugs and partial orphan drugs then common drugs. This
could be based on the concerted effort to include rare diseases on the list of
compassionate allowances.40 It is also possible that individuals with a rare disease
diagnosis have access to resources that help them to apply for Social Security benefits,
which makes them eligible for Part D. The large share of orphan drug spending
attributable to individuals under the age of 65 indicates the overall need for public
programs to help rare disease patients access treatments. Future research should explore
the additional demographic and diagnosis characteristics of Medicare enrollees on
Medicare. Geographic variation based on the accessibility of rare disease providers and
programs to connect individuals with additional assistance may provide additional
information about equity issues or barriers to enrollment.
Rare Cancer
A total of $24.01 billion is attributed to orphan only rare cancer drugs and an
additional $16.34 billion is attributed to rare cancer drugs with combined orphan and
non-orphan indications. The average aggregate total cost of rare oncology drugs ($97.9
million) was higher than non-cancer orphan drugs ($70.4 million), but the costs per
beneficiary were significantly higher for non-cancer drugs ($68,152) compared to rare
cancer orphan drugs ($33,114). The total sum of all rare cancer spending for all years was
$40.347 billion or 39.43% of all orphan drug spending from 2013 to 2017. This is
consistent with the 2013 finding that oncology drugs represented 40.7% of orphan drug
spending in a study of sales data.31
Individuals over the age of 65 account for 78.69% of the expenditures for rare
oncology drugs. By contrast, individuals over the age of 65 account for 6.77% of non-
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oncology products. It is possible that beneficiaries are receiving medications for both
cancer and non-cancer orphan drugs, we cannot make determinations about the diagnostic
characteristics of rare disease patients on Part D.
Drugs with multiple orphan indications
Per beneficiary costs for orphan drugs with multiple indications are not
statistically significant compared to per beneficiary costs for orphan drugs with one
indication. Previous studies have found that drugs with multiple orphan indications have
higher prices,15 however, the disease prevalence of the first indication is an additional
contributing factor which was not investigated in this study.70 The range in values for
costs per beneficiaries for orphan drugs with a single orphan indication ranges from
$90.42 per beneficiary to $1,306,221 per beneficiary. Orphan drugs with multiple
indications range from $142.96 to $437,481.20 per beneficiary. This range provides
evidence for the large range of costs in orphan drug spending. By contrast, the minimum
per beneficiary cost for common drugs is $.01 per beneficiary. Drugs that entered the
market as an orphan drug first or that are only indicated as orphan drugs are associated
with higher costs per beneficiaries.
Policy implications and future research
Although the overall proportion of orphan drug spending is low, the per
beneficiary costs and the cost share individuals may be responsible for are quite high if
coinsurance is utilized. This is consistent with other findings related to orphan and
specialty drugs in the U.S.13,29,31 Policies need to be implemented to curb the burden of
high costs of drugs in the United States. There have been a number of strategies proposed
by researchers and advocates which focus on promoting competition, increasing
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transparency, and utilizing negotiation techniques.71 One of the most compelling policy
changes would be to allow CMS to negotiate drug prices directly with pharmaceutical
companies, a strategy that has been successful for our international counterparts.71–73
Legislative efforts to implement these types of policies are consistently blocked by
lobbying efforts by pharmaceutical companies.
As policies are formulated to control drug costs, it is essential to curb spending
while not stifling innovation. Although pricing is an issue for orphan drugs, there is a
large unmet need for patients with over 6,000 rare diseases not having any approved
therapy. Understanding the patient impact and ethical implications of access to orphan
therapies is crucial when formulating new policies or revisiting the incentives outlined in
the ODA.74,75 Increasing the transparency of the orphan drug development process will be
critical to formulating strategies that can more successfully balance competing cost and
access needs.14,18
This paper provides additional evidence for the use of Medicare by individuals
under the age of 65 who have high drug costs. Without access to Medicare, individuals
may not be able to access these drugs. Future research should investigate the ease of
gaining access to orphan drugs under Medicare to understand if there are claim denials
for orphan drugs. Although orphan drug spending only represented 7% of expenditures in
Medicare Part D, that is unlikely to represent the need. Additional research should be
conducted to determine how easy it was to gain access to Medicare for rare disease
beneficiaries.
Some beneficiaries who require orphan drugs may also be dual beneficiaries with
Medicaid. Additionally, many pharmaceutical companies provide patient assistance
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programs to provide reduced cost drugs or waive copays. Understanding how these
programs contribute to overall costs and medication adherence decisions would provide a
more complete picture for the orphan drug cost ecosystem. In the future, health insurance
plans designed for individuals with high drug costs may be necessary to curb unnecessary
spending, while providing needed access.
Future research should be conducted to explore beneficiary level data both to
capture total costs per rare disease patient and the cost-sharing mechanisms. There are
clear cost differences for drugs on and off formularies,30 it is critical for patients with
high cost drugs to have an easy way to identify the correct plan. It may not be possible
for rare disease patients on multiple medications to choose a plan that would provide an
affordable way to access all needed drugs. Research should also be conducted to
determine how patients navigate plan enrollment.
The costs per beneficiary have the potential to be very large, even after
catastrophic caps are met.30,46,60 Growing concerns related to the high out of pocket costs
for U.S. patients may require that we restructure our medical assistance programs. The
potential costs an individual may be responsible for may be prohibitive for most
individuals contributing to overall financial toxicity or worse health outcomes.
Demographic and geographic variability should be explored to determine if inequities are
developing due to programmatic structures.
As conversations related to health care reform and controlling costs continue,
understanding spending for the rare disease population will help ensure better health and
financial outcomes. Internationally, rare disease country specific plans allow a holistic
approach for addressing the needs of the rare disease population.76,77 Addressing rare
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disease needs in new national policy could provide a better roadmap for cost-effective
patient centric initiatives. Some states have begun to form Rare Disease Advisory
Councils and although many policy initiatives are critical to address at the state level,
there should be an investment in both state and country level planning. Healthcare policy
initiatives should include the patient voice and the high-costs of orphan drugs should
ensure that rare disease patient advocates have a seat at the table.
Conclusion
Although orphan drug spending comprises a relatively small share of overall
Medicare Part D expenditures, the per beneficiary and per claim costs can be very high.
Almost half of the costs associated with orphan drugs are attributed to beneficiaries under
the age of 65. Rare cancer drugs that are only indicated for rare use represent 3.6% of all
spending in Medicare Part D. Drug costs will continue to be a significant portion of our
medical costs. More strategies must be undertaken to address the high costs and ensure
appropriate access to patients who need high cost drugs. Previous studies on Part D
trends have focused on specialty drugs or a subset of orphan drug spending. The high cost
and growth of orphan drugs provides a compelling reason to conduct this analysis and
future studies should focus on drug use and total beneficiary costs.
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CHAPTER 5
CONCLUSION
There are an estimated 30 million patients in the United States living with one or
more rare diseases.1 There is limited research on most rare diseases which perpetuates
challenges for patients, researchers, and medical professionals.4,6,7 High-quality data and
an understanding of the patient experience are critical to establishing effective healthcare
infrastructure that maximizes positive patient health outcomes and minimizes costs. This
dissertation research is comprised of three papers related to key aspects of the rare
disease experience in the United States.
For most rare diseases, basic information such as the natural history of the disease
and epidemiological data is limited or missing.4,10 The importance of including the
patient voice has become an established theme in the rare disease community and
literature.32–35 However, it is important to note the differences in data availability for
diseases with and without an orphan drug. Diseases with orphan drugs are more likely to
have patient organization representation, which are often critical for driving research.33–35
Other infrastructure such as the ability to code and track the disease in electronic health
systems is also more likely if a disease has a drug, which may make it is easier to
establish treatment protocols or justify medical needs to an insurance company.
Patients interfacing with insurance companies often feel that the insurance
company does not understand the medical necessity of certain medical procedures or
products. Caregivers describe the necessity of becoming an expert on the disease or
relying on medical professionals in the care team to navigate the entire insurance
experience.36 Patients are often overwhelmed trying to identify and apply for programs
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that can help them cover medical expenses. Finding the appropriate mix of insurance and
social service supplemental support can be complex and there are few mechanisms to
help patients plan their long-term health care needs.
Medicare Part D provides drug coverage for individuals over the age of 65 or with
a qualifying disability. Roughly 85% of Medicare Part D beneficiaries are over the age of
65, but costs per claim are higher for individuals under the age of 65. The total
expenditures for orphan drugs in Medicare Part D are around 10% of all expenditures, but
the high costs for individuals under the age of 65 indicates the need to consider this group
when preparing for future healthcare expenditures and instituting any healthcare reforms.
Our healthcare infrastructure is currently not equipped to capture detailed
information about rare diseases or track diseases across information sources. Within
insurance, patients have a complicated journey to navigate what will be covered and the
onus falls on patients or caregivers to track the details of healthcare interactions and
navigate program eligibility. Insurance and medical assistance programs allow patients to
access needed services or benefits, but geographic inequities have been described.
Additional research will be necessary to determine how many rare disease patients have
been denied enrollment in Medicare or Medicaid benefits and the associated wait times to
receive a determination of eligibility.
Policy implications
All healthcare policy initiatives should be patient-centric and consider patient
privacy protections. This research did not address demographic equity issues, but based
on the persistent inequities in the U.S. healthcare system, future research should identify
and address disparities based on race and educational attainment. Different geographic
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regions may have better access to medical knowledge through increased access to elite
providers or institutions. Additionally, differences in access based on state-based
eligibility differences, especially related to Medicaid expansion, can also lead to
geographic disparities.
Expanding medical technologies and investing in an increased medical
understanding of rare diseases, must also be met with ensuring that all patients can
benefit to avoid further reinforcing health disparities in this country. One way to ensure
that this is accomplished is to leverage telemedicine to access providers outside of
geographic areas. Another solution is to ensure that insurance plans allow for patients to
see disease specialists outside of their network without incurring additional costs,
especially in cases where only a handful of medical experts may exist. It is also important
that diseases without current pharmaceutical investment still have representation in policy
initiatives and opportunities to establish natural history studies to generate basic research.
It is critical to continue to invest in research for rare diseases and find ways to
continue to educate clinicians, insurance companies, and policymakers. Health
information websites and institutions should commit to higher data quality, including
providing more attribution to the previous research that has been conducted so the source
and relevance of the data can be assessed. The U.S. should also continue to participate
and implement efforts related to standardized nomenclature of rare diseases, such as the
work being conducted by the Monarch Initiative and IRDiRC.25,27 The U.S. should also
commit to adopting the infrastructure that can help increase the visibility of rare diseases,
such as establishing a plan to institute the ICD-11 codes in a reasonable timeframe.
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Orphan drugs represent a large part of the focus for rare diseases, but are only
available for about 300 of the identified 6,500 rare diseases.37 Orphan drug prices are
very high in the United States and represent higher per capita spending in programs for
Medicare Part D compared to drugs for common conditions. However, these treatments
are often life altering for patients, as is the case for individuals with spinal muscular
atrophy. Payers are not always equipped to evaluate the benefit of these drugs and
patients and caregivers are often tasked with building a case for their coverage when a
new drug enters the market, which can delay access. Future policies should address
strategies to help prepare insurance companies for newly approved drugs.
The increasing use of genetic information in the drug development process has the
potential to change how we treat rare diseases.38–41 However, our current infrastructure
may not be equipped to track genetic differences for patients and inequities may dictate
who can access these advanced therapies. Especially for treatments that have a high cost.
Changes in pharmaceutical pricing could address some of these concerns, including
allowing CMS to directly negotiate drug prices with pharmaceutical companies. As a
country, we will need to find policies that can balance how we incentivize research and
development, our desire for medical innovation, patient access, and overall costs.
To realize any of our policy goals it we must continue to participate
internationally and include key stakeholders in policy initiatives. Rare diseases are a truly
global public health challenge and should be addressed as such, while ensuring unique
features of the U.S. healthcare system and our demographics are accounted for in
implementation. We should recognize the unique role clinicians play as the front line of
rare disease identification and treatment. Clinicians must be involved in both generating

152

and receiving knowledge about rare diseases and as a partner in connecting patients to
appropriate resources. Clinicians are critical in helping capture data related to patient
prevalence and providing details related to the medical necessity of certain treatments,
therapies, and medical equipment. Payers, including private insurance companies,
Medicare, and Medicaid, need to understand the importance of patient access to care that
is deemed medically necessary. Finding better ways to evaluate these recommendations
in a timely manner, especially for diseases with a small patient population can help
patients financially prepare for needed medical expenses and cut down on more serious
and costly medical complications.
Patients make up the final group of stakeholders that must hold a seat at the table
for any policy reform efforts. It is important to recognize the different experience that
patients may face if their disease does not have an established patient organization or if
the disease has not been widely studied. It is important to facilitate programs that will
help connect patients to information and to access healthcare, especially if experts fall
outside of their geographic area or insurance network. It would also be beneficial to
identify ways to drive collective action without splintering resources or generating too
many independent data sources that cannot be integrated and shared through data sharing
agreements. The rise of patient advisory councils or rare disease committees at the state
level and for drug development have been a driving force in progress to date.7,33,35
However, a rare disease national plan should be developed for the United States to keep
pace with our European and international colleagues and to chart priority areas of growth
and investment.
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APPENDICES
APPENDIX A
LOGISTIC REGRESSION OUTPUT FOR DISEASE NAMING CONVENTIONS
Statistically significant coefficients are indicated using the following symbols: *=p<.05,
**=p<.01, ***=p<.001
Table A: Broad name
Orphan drugs
Rare cancers
Orphan drug* Rare cancer
Constant

Coefficient SE
1.185
0.717
0.767
0.73
-1.186
0.977
-1.386*
0.559

Table B: Specific name
Orphan drugs
Rare cancers
Orphan drug* Rare cancer
Constant

Coefficient SE
1.846
1.149
0.000
1.451
0.252
1.616
-2.944**
1.026
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APPENDIX B
LOGISTIC REGRESSION OUTPUT FOR DATA WEBSITES WITH
PREVALENCE ESTIMATES
Statistically significant coefficients are indicated using the following symbols: *=p<.05,
**=p<.01, ***=p<.001
Table A: Prevalence estimate listed in GARD
Coefficient
SE
Orphan drugs
0.747
1.268
Rare cancers
-1.210
1.202
Orphan drug* Rare cancer
-1.210
1.599
Constant
-2.944
1.026
Table B: Prevalence estimate listed in NORD
Coefficient
SE
Orphan drugs
2.944**
1.119
Rare cancers
1.846
1.149
Orphan drug* Rare cancer
-3.232*
1.353
Constant
-2.944**
1.026
Table C: Prevalence estimate listed in Orphanet
Coefficient
SE
Orphan drugs
0.811
0.645
Rare cancers
0.405
0.639
Orphan drug* Rare cancer
-1.212
0.908
Constant
-0.405
0.456
Table D: Prevalence estimate listed in Genetics home
reference
Coefficient
SE
Orphan drugs
2.197*
Rare cancers
1.099
Orphan drug* Rare cancer
-3.296**
Constant
-2.197**

0.869
0.907
1.256
0.745

Table E: Prevalence estimate listed in Genereviews
Coefficient
SE
Orphan drugs
1.558
1.168
Rare cancers
1.558
1.168
Orphan drug* Rare cancer
0.000 Omitted
Constant
-2.944**
1.026
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Table F: Prevalence estimate listed in Medscape
Coefficient
SE
Orphan drugs
2.744*
1.12
Rare cancers
1.558
1.168
Orphan drug* Rare cancer
-0.952
1.332
Constant
-2.944
1.026
Table G: Prevalence estimate listed in OMIM
Coefficient
SE
Orphan drugs
17.785 Omitted
Rare cancers
15.993
0.874
Orphan drug* Rare cancer
-17.322
0.974
Constant
-18.190
0.456
Convergence not achieved
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APPENDIX C
LINEAR REGRESSION OUTPUT FOR PREVALENCE ESTIMATES WITH
DATA QUALITY FACTORS BY DISEASE
Statistically significant coefficients are indicated using the following symbols: *=p<.05,
**=p<.01, ***=p<.001
Table A: Number of estimates
Orphan drugs
Rare cancers
Orphan drug* Rare cancer
Constant

Coefficient SE
7.450
2.212
2.500
2.212
-0.950
3.128
0.800
1.564

Table B: Number of quality estimates
Coefficient SE
Orphan drugs
1.400*
0.539
Rare cancers
0.800
0.539
Orphan drug* Rare cancer
0.100
0.763
Constant
0.200
0.381
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APPENDIX D
LOGISTIC REGRESSION OUTPUT FOR PREVALENCE ESTIMATES WITH
DATA QUALITY FACTORS BY ESTIMATE
Statistically significant coefficients are indicated using the following symbols: *=p<.05,
**=p<.01, ***=p<.001
Table A: Author
Orphan drugs
Rare cancers
Orphan drug* Rare cancer
Constant

Coefficient
SE
<.0001
0.15
-0.227
0.141
0.100
0.16
0.500***
0.135

Table B: Date
Orphan drugs
Rare cancers
Orphan drug* Rare cancer
Constant

Coefficient
SE
-0.006
0.136
-0.324*
0.127
0.076
0.145
0.688***
0.122

Table C: Attribution
Coefficient
Orphan drugs
Rare cancers
Orphan drug* Rare cancer
Constant

0.180
0.019
-0.149
0.563**

SE
0.202
0.19
0.216
0.181

Table D: All quality factors
Coefficient
Orphan drugs
Rare cancers
Orphan drug* Rare cancer
Constant

0.053
-0.056
0.008
0.250*
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SE
0.119
0.112
0.127
0.107

APPENDIX E
LOGISTIC REGRESSION OUTPUT FOR PREVALENCE INFRASTRUCTURE
VARIABLES
Statistically significant coefficients are indicated using the following symbols: *=p<.05,
**=p<.01, ***=p<.001
Organization
Orphan drugs
Rare cancers
Orphan drug* Rare cancer
Constant

Coefficient
SE
3.121***
0.839
1.792*
0.722
-1.792
1.142
-1.386*
0.559

Disease specific organization
Coefficient
SE
Orphan drugs
2.197*
0.869
Rare cancers
1.099
0.907
Orphan drug* Rare cancer
-1.946
1.123
Constant
-2.197*
0.745
Registry
Orphan drugs
Rare cancers
Orphan drug* Rare cancer
Constant

Coefficient
SE
3.145**
1.12
1.210
1.202
-2.797*
1.4
-2.944**
1.026

Medical center
Orphan drugs
Rare cancers
Orphan drug* Rare cancer
Constant

Coefficient
SE
2.140**
0.775
1.253
0.668
-1.253
1.109
-0.405
0.456

ICD-10 specific
Orphan drugs
Rare cancers
Orphan drug* Rare cancer
Constant

Coefficient
SE
2.539*
1.123
1.210
1.202
-1.423
1.369
-2.944
1.026

ICD-11 specific
161

Orphan drugs
Rare cancers
Orphan drug* Rare cancer
Constant

Coefficient
SE
2.582***
0.794
0.636
0.812
-0.636
1.065
-1.734**
0.626
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APPENDIX F
LINEAR REGRESSION OUTPUT FOR PREVALENCE INFRASTRUCTURE
VARIABLES
Statistically significant coefficients are indicated using the following symbols: *=p<.05,
**=p<.01, ***=p<.001
Table A: Number of organizations
Coefficient
SE
Orphan drugs
4.200***
1.107
Rare cancers
1.850
1.107
Orphan drug* Rare cancer
-0.800
1.566
Constant
0.250
0.783
Table B: Number of medical centers
Coefficient
SE
Orphan drugs
15.350*
5.928
Rare cancers
7.150
5.928
Orphan drug* Rare cancer
6.950
8.384
Constant
1.500
4.192
Table C: Number of clinical trials
Coefficient
SE
Orphan drugs
25.55
84.229
Rare cancers
41
84.229
Orphan drug* Rare cancer
273.9*
119.117
Constant
0.9
59.559
Table D: Number of active clinical trials
Coefficient
SE
Orphan drugs
8.200
24.496
Rare cancers
11.150
24.496
Orphan drug* Rare cancer
83.250*
34.643
Constant
0.250
17.321
Table E: PubMed results
Orphan drugs
Rare cancers
Orphan drug* Rare cancer
Constant

Coefficient
SE
2054.150 1702.497
621.100 1702.497
4733.800 2407.694
425.100 1203.847

Table F: PubMed incidence or prevalence results
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Orphan drugs
Rare cancers
Orphan drug* Rare cancer
Constant

Coefficient
SE
100.450
122.27
85.050
122.27
399.450*
172.916
41.700
86.458
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APPENDIX G
QUALITATIVE INTERVIEW SCRIPT
Interview Questions
Hi, thank you for taking the time to speak with me today. I am interested in speaking
today about your health insurance experience.
Obtaining insurance
1. Have you ever experienced difficulty getting insurance or experienced an
extended period, more than three months, of not having insurance? Could you tell
me about that experience?
2. Are you satisfied with your current health insurance?
a. Can you tell me anything about what type of insurance you have (public,
private, from an employer, etc.)?
Coverage/ Orphan drugs
3. Can you tell me about a time that you might have experienced any difficulties
obtaining medical care based on your insurance? (This might include things such
as seeing your preferred doctor or having treatments or medications covered)
4. Did you ever experience a significant change in your insurance?
a. What was your role in bringing that about?
b. Was there anyone who helped you navigate or bring about that change?
Cost-sharing
Many insurance plans use a variety of methods to share the cost between insurance and
the patient. I am now going to ask you about a few of these different methods. Don’t
worry if you are unfamiliar with any of these terms or concepts, just tell me about
anything you do know or believe you have experienced.
5. A premium is the amount of money patients must pay for their insurance, usually
on a monthly basis. Do you know if you have a premium and how much you pay?
6. A copay is a fee that some people have to pay before certain types of
appointments or doctor’s appointments. Usually, you would pay this when you
arrive at the doctor. Do you know if you are required to pay a copay?
7. Sometimes insurance uses coinsurance, where insurance will cover some portion
of the medical expense and the patient must cover the rest. Often you would
receive this as a bill after you have attended your appointment. Do you know if
your insurance company requires coinsurance
8. A deductible is sometimes set by insurance companies and is the amount a patient
needs to spend before the insurance company will cover any additional costs. Do
you know if you have a deductible and if you do, how much it is for?
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9. Is there anything else about your experience with fees and payments you
experienced?
Health literacy
10. In general, how comfortable are you navigating your insurance?
a. Do you think your comfort level has changed over time?
Navigating the system
11. Has anyone helped you understand or navigate the system, this might include
things like organizations, friends, or peer-support networks?
Additional Assistance
12. Can you tell me if there any other programs or services that you are able to use
that provide any financial or medical support?
a. How easy was it to access this source of support?
b. How did you learn about these resources?
Final Questions
13. If you could make a wish list to make your experience better, what would that
include?
14. Is there anything else you would like me to know?
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APPENDIX H
QUALITATIVE CODEBOOK

Code

Description

Assistance

Financial or in-kind assistance received to cover the cost of medical
treatments, equipment, services, or procedures. This also includes
information related to how easy it was to access this type of support.

1.1

Early
intervention

Service and supports that are available to children younger than three
years old with developmental delays and disabilities. Programs exist in
every state and covered services are based on needs but often include
speech and physical therapy.

1.2

Grants

Financial assistance for medical equipment, treatments, services, or
procedures that are received from funds that the participant applied to
from the government, organizations, or foundations.

1.3

None

When the participant stated that they do not access any additional
financial assistance or support programs.

1.4

Organization
or companies

Financial or in-kind assistance for medical equipment, treatments,
services, or procedures that is provided by a private or non-profit
organization.

1.5

Peers or
family

Financial or in-kind assistance for medical equipment, treatments,
services, or procedures that is provided by peers, friends, or family
members.

1.6

Pharma

Financial or in-kind assistance from pharmaceutical companies.
Usually related to accessing low cost treatments or to cover the copays and associated fees for the treatment.

1.7

School

Financial or in-kind assistance for medical equipment, treatments,
services, or procedures that is provided by schools or the school
district.

1.8

State

Financial or in-kind assistance for medical equipment, treatments,
services, or procedures that is provided by the state.

Cost-sharing

The portion of costs that the individual is responsible for in order to

1.

2.
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access
2.1

Caps

Any experience related to limits on the benefits the insurance company
will cover in a plan year.

2.2

Coinsurance

Any experience related to coinsurance.

2.3

Copay

Any experience related to copays.

2.4

Deductible

Any experience related to deductibles.

2.5

Other

Descriptions of other types of financial payments or cost sharing an
individual has experienced.

2.6

Out of pocket
maximum

Descriptions of the limit an individual is required to pay before
insurance will cover the rest of their costs within a plan year.

2.7

Premium

Any experience related to premiums.

2.8

Savings

Any experience related to an individual’s actions to attempt to save
money for the insurance company. This could include deciding not to
submit certain expenses or specific strategies meant to save money.

Coverage

Descriptions of the health insurance coverage experience for medical
procedures, equipment, providers, and services.

3.1

Consistent

The participant indicates that they always had coverage and did not
experience a period of interrupted health coverage.

3.2

Equipment

Experiences related to access to equipment and medical supplies.

3.3

Hospital

Experiences related to access and coverage of hospital services.

3.4

Nursing

Experiences related to access and coverage for nursing services.

3.5

Providers

Experiences related to access and coverage to medical providers.

3.6

Therapy

Experiences related to access and coverage for therapy; including
physical, occupational, and speech therapies.

3.7

Treatments

Experiences related to access and coverage for treatments; including

3.
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medical procedures, pharmaceutical products, and vaccines.
4.

Genetics

Any description of genetic testing, genome sequencing, or the impact
of genetic information on decision making.

5.

Health

Experiences related to the patient’s health, disease progression, or
medical recommendations.

5.1

Consequence
s

Real, perceived, or hypothetical health consequences of delays or
denials in coverage.

5.2

Diagnosis

Experiences related to how diagnosis impacted the patient’s access or
coverage experience.

5.3

Doctor rec

Information related to the difference between a medical professional’s
recommendations for care and the health insurance company’s
coverage.

5.4

Transition

Experiences related to the coverage and care transitions patients
experience as they age.

Health
literacy

An individual’s ability to obtain, process, and understand health
information and systems to make health decisions.

6.1

Knowledge

Descriptions related to how well an individual understands the
healthcare system and the health insurance system.

6.2

Navigating

Experiences related to how an individual can navigate and work
through the health insurance system to access healthcare.

Improvement
s

Discussion on any improvements that the participant believes should
be made to the system.

7.1

Automated

Discussion related to changes to automate aspects of the system.

7.2

Centralized

Discussion related to centralizing resources or information.

7.3

Communicati
on

Discussion related to improving communication.

7.4

Cost

Discussion related to changes in the costs of the system.

6.

7.
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7.5

Knowledge

Discussion related to changes in the insurance company’s knowledge
or comprehension of the experience of patients and families.

7.6

Main thing

The thing that the individuals indicated would be the most critical
change to improve their insurance experience.

7.7

Personnel

Discussion related to changes in personnel at health insurance
companies.

7.8

Time

Discussion related to changes in the time associated with interacting
with the system.

7.9

Transparency

Discussion related to improvements around transparency.

7.10

User friendly

Discussions related to how user friendly the system is to navigate.

Involvement

Experiences related to an individual’s level of involvement or
participation in achieving coverage or in medical decision making for
their loved one.

8.1

Active

Experiences where an individual took an active role in health insurance
coverage or access.

8.2

Passive

Experiences where an individual took a passive role in health
insurance coverage or access.

8.3

Preplanning

Experiences where an individual took action prior to when coverage
was necessary.

Life

Descriptions of the interplay between life decisions and the medical or
health insurance experience.

9.1

Children

Descriptions related to family planning or having additional children.

9.2

Home

Descriptions related to setting up a home or where an individual is
willing to live.

9.3

Mental health

Descriptions related to mental health.

9.4

Uncertainty

Descriptions related to the fear of the unknown or uncertainty of the
future.

8.

9.
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9.5

Work

Descriptions related to employment decisions.

Obstacles

Descriptions of the challenges participants have experienced while
trying to access their health insurance coverage or experiences faced
while working with their health insurance company.

10.1

Approval

Experiences related to what the insurance company is willing to
approve for coverage.

10.2

Bounced

Experiences related to how many people or departments the participant
must interact with before their issue is resolved, or their question is
answered.

10.3

Changes

Experiences related to changes in the insurance policy or company.

10.4

Coding

Descriptions related to how coding impacted insurance coverage.

10.5

Cost

Experiences related to the cost or financial barriers to coverage.

10.6

Coverage

Descriptions related to the coverage experience when an individual is
covered by multiple insurance plans and the interplay between the
coverage.

10.7

Documentati
on

Experiences related to the providing the necessary documentation or
paperwork.

10.8

Incomplete
information

Experiences related to receiving incomplete information from the
insurance company.

10.9

Knowledge

Experiences related to the overall knowledge or comprehension of the
people working within the insurance system.

10.10

Network

Experiences related to accessing providers or treatment centers that are
not in the network for the insurance plan.

10.11

Options

Descriptions related to available options for choosing insurance
providers or the flexibility of the type of plans that are available.

10.12

Qualifying

Experiences related to gaining coverage or qualifying for a certain type
of insurance plan.

10.13

Redundancy

Experiences related to the redundancy or repetition of the system.

10.
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10.14

Time

Experiences related to the time it takes to interact with insurance, to
navigate the system, or to access coverage.

11.

Politics

Any discussion on how politics play into feelings of uncertainty or
decision making.

Pre-existing
condition

Any discussion related to preexisting conditions.

12.

Privilege

Any discussion related to how the participant’s experience compares to
others or the struggle that other individuals may be experiencing. This
could be in relation to their successes or their commentary about
overall challenges for others in a similar position.

13.

Recruitment

Offers to help recruit for the study.

14.

Satisfaction

Descriptions related to an individual’s satisfaction related to health
insurance.

Trust

Descriptions related to the trust an individual has for their insurance
company.

Support

Experiences related to receiving emotional, mental, or informational
support. This includes both finding and accessing health services and
utilizing connections to feel better about an individual’s situation. This
does not include financial support.

15.1

Coordination

Any description of multiple parties working together to solve a health
insurance issue or provide emotional support.

15.2

Early
intervention

Experiences related to support provided by the early intervention
program.

15.3

Insurance
Company

Experiences related to support provided by the health insurance
company.

15.4

Organizations Experiences related to support provided by organizations, including
non-profits or other support agencies.

15.5

Peers

Experiences related to support received by peers, friends, or family.

15.6

Providers

Experiences related to support provided by medical providers

11.1

14.1

15.
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including physicians, nurses, therapists, or other hospital workers.
15.7

School

Experiences related to support provided by the school system or
individuals who work at the school.

15.8

Social media

Experiences related to support received through social media.

15.9

Social
workers

Experiences related to support provided by social workers.

Type

Descriptions related to the type of insurance coverage an individual
has for their child.

16.1

Employer

Experiences related to employer sponsored health insurance.

16.2

Public

Experiences related to forms of public insurance coverage.

16.
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